23-26 June 2021 Virtual Conference
![]() |
![]() |
![]() |
![]() |
PO-019 | Modeling Disease Burden of Nonalcoholic Fatty Liver Disease (NAFLD) in Japan | Junko Tanaka | ![]() |
![]() |
|||
PO-33 | Association between sarcopenic obesity and nonalcoholic fatty liver disease and fibrosis detected by fibroscan | Karn Wijarnpreecha | ![]() |
![]() |
|||
PO-043 | Preliminary pharmacokinetics and safety in healthy volunteers of VIR-3434, a monoclonal antibody for the treatment of chronic hepatitis B infection | Wendy Re | ![]() |
![]() |
|||
PO-048 | Alcohol-related liver disease phenotype impacts survival after an acute variceal bleeding episode | Ares Villagrasa | ![]() |
![]() |
|||
PO-051 | Aiming for HCV elimination - Optimizing DAA therapy by characterisation of patients lost to follow up (LTFU) in a large real world setting - Data from the German Hepatitis C-Registry (DHC-R) | Yvonne Serfert | ![]() |
![]() |
|||
PO-052 | Persistent long-term risk of liver related complications in hepatitis C virus patients after antiviral therapy - Data from the German Hepatitis C-Registry (DHC-R) | Yvonne Serfert | ![]() |
![]() |
|||
PO-060 | Quantification of polyreactive immunoglobulin G facilitates diagnosis of autoimmune hepatitis | Bastian Engel | ![]() |
![]() |
|||
PO-068 | Prospective independent confirmation of guideline defined hepatitis C screening strategies within the Check-Up examination in the primary care setting | Johannes Wiegand | ![]() |
![]() |
|||
PO-75 | Irreversible electroporation vs radiofrequency ablation for hepatocellular carcinoma: A single centre propensity matched comparison | Elliot Freeman | ![]() |
![]() |
|||
PO-080 | End-of-treatment HBsAg, HBcrAg and HBV RNA levels predict sustained response and HBsAg loss in chronic hepatitis B patients | Sylvia Brakenhoff | ![]() |
![]() |
|||
PO-081 | Economic consequences of anti-HCV treatment of patients diagnosed through screening in Italy: a prospective modeling analysis. | Claudia Simonelli | ![]() |
![]() |
|||
PO-089 | Survivin inhibition ameliorates liver fibrosis via inducing senescence in hepatic stellate cells | Sachin Sharma | ![]() |
![]() |
|||
PO-094 | Automated quantitation of histological features could predict mortality in patients with severe alcoholic hepatitis | Luke Tyson | ![]() |
![]() |
|||
PO-106 | Social outcomes in patients with biliary atresia: a systematic review | Emma Alexander | ![]() |
![]() |
|||
PO-111 | One-year safety results of the Nuc-Stop Study, an open-label study on stopping antiviral therapy in HBeAg negative chronic hepatitis B | Asgeir Johannessen | ![]() |
![]() |
|||
PO-117 | Sulfated Steroids and Bile Acids and Dopamine Metabolites are Associated with Favorable Outcomes after Fecal Transplant in Alcohol Use Disorder | Jasmohan Bajaj | ![]() |
![]() |
|||
PO-127 | Quality of life is impaired in both physical and mental health domains in patients with Autoimmune Hepatitis (AIH): A systematic review and meta-analysis of Patient-Reported Outcome Measures (PROMs) | Selena Dixon | ![]() |
![]() |
|||
PO-131 | From screening to therapy: Anti-HCV screening and linkage to care in a network of general practitioners and a private gastroenterology practice | Johannes Wiegand | ![]() |
![]() |
|||
PO-133 | Repression of fatty acid oxidation in steatohepatitic-HCC is mediated by E2F1 and E2F2 transcription factors | Francisco Gonzalez-Romero | ![]() |
![]() |
|||
PO-134 | Genetic variation in the mitochondrial glycerol-3-phosphate acyltransferase is associated with liver injury | Aaron Hakim | ![]() |
![]() |
|||
PO-147 | Hepatitis B vaccine NON-RESPONDERS show higher frequencies of REGULATORY B CELLS, but lower levels of IL-10 expression compared to responders | Laureen Pohl | ![]() |
![]() |
|||
PO-153 | Prevalence and origin of rare HCV Genotypes in DAA-naive and DAA-experienced patients | Julia Dietz | ![]() |
![]() |
|||
PO-159 | Target engagement and evidence of efficacy with PXL770, a novel direct AMP-Kinase activator, in a 4-week PK/PD trial in patients with NAFLD | Vlad Ratziu | ![]() |
![]() |
|||
PO-167 | Derivation and validation of the NAFLD cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis and to predict liver-related outcomes | Christian Labenz | ![]() |
![]() |
|||
PO-175 | A cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral target | Gatan Ligat | ![]() |
![]() |
|||
PO-186 | Real-world experience of mTOR inhibitors in liver transplant recipients in a region where living donation is predominant | Pil Soo Sung | ![]() |
![]() |
|||
PO-187 | Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus | Ellen Driever | ![]() |
![]() |
|||
PO-190 | Patients with LIVER CIRRHOSIS - SATISFACTION in a NURSE-LED outpatient clinic | Marie Louise S. Hamberg | ![]() |
![]() |
|||
PO-195 | Role of Mcpip1 in obesity-induced hepatic steatosis as determined by myeloid and liver-specific conditional knockouts | Natalia Pydyn | ![]() |
![]() |
|||
PO-196 | Chronic liver damage favours induction of CD44v6 epithelial cells and subsequent liver carcinoma formation | Akshaya Srikanth | ![]() |
![]() |
|||
PO-205 | A new prediction equation for estimating body weight in cirrhotic patients with refractory ascites | Bruna Alves | ![]() |
![]() |
|||
PO-210 | A Dose-Finding, Positive Proof of Concept study of HTD1801 in Patients with Primary Sclerosing Cholangitis | Kris Kowdley | ![]() |
![]() |
|||
PO-212 | Early Renal Dysfunction Post Liver Transplant Predicts Long-term Adjudicated Cardiovascular Events | Ramzi Hassouneh | ![]() |
![]() |
|||
PO-216 | Liver resident Natural Killer cells are the dominant source of Fas ligand during chronic Hepatitis B virus mediated liver damage | Adrian Kuipery | ![]() |
![]() |
|||
PO-218 | Incidence and resolution of steatohepatitis in patients receiving entecavir for chronic hepatitis B | Yiwen Shi | ![]() |
![]() |
|||
PO-223 | Precision-cut liver slices as a dynamic tool to model liver fibrosis in vitro | Liza Dewyse | ![]() |
![]() |
|||
PO-230 | Semaglutide in patients with non-alcoholic steatohepatitis: subgroup analysis of a randomised, placebo-controlled phase 2 trial | Sven Francque | ![]() |
![]() |
|||
PO-231 | Effect of subcutaneous semaglutide on quality-of-life in patients with non-alcoholic steatohepatitis | Manuel Romero-Gómez | ![]() |
![]() |
|||
PO-235 | Combined PD-1 blockade plus IL-15 treatment restores HBV-specific CD8 T cell reactivity in short-term nucleos(t)ide analogue treated eAg chronic hepatitis B | Julia Peña Asensio | ![]() |
![]() |
|||
PO-240 | Identification of a CD8 T cell population with a transcriptional profile consistent with non-specific hepatocyte killing in the inflamed human liver of chronic hepatitis B patients | Shirin Nkongolo | ![]() |
![]() |
|||
PO-246 | CD44v6gp38 large extracellular vesicles in gall bladder survival prognosis - a pilot study | Bingduo Wang | ![]() |
![]() |
|||
PO-247 | On-treatment HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg negative patients | Teresa Broquetas | ![]() |
![]() |
|||
PO-250 | prognostic value of a nomogram predicting microvascular invasion for patients with hepatocelluar carcinoma | Liying Ren | ![]() |
![]() |
|||
PO-251 | Definition of healthy ranges for alanine aminotransferase levels: a 2020 update | serena pelusi | ![]() |
![]() |
|||
PO-254 | Effectiveness of obeticholic acid in patients with primary biliary cholangitis stratified by biochemical marker status in the real-world setting in the United States | Amy Law | ![]() |
![]() |
|||
PO-258 | Helicases DDX5 and DDX17 regulate hepatitis B virus transcriptional fidelity and RNA processing in infected human primary hepatocytes | Guillaume GIRAUD | ![]() |
![]() |
|||
PO-260 | Risk factors for chronic hepatitis B among 0.5 million Chinese adults | Elizabeth Hamilton | ![]() |
![]() |
|||
PO-262 | Blood-derived extracellular vesicles of patients with liver cirrhosis and acute-on-chronic liver failure display immunomodulatory functions | Mona-May Langer | ![]() |
![]() |
|||
PO-266 | Liver volume measurement predicts development of hepatic encephalopathy in chronic hepatitis b patients | Changhyun Lee | ![]() |
![]() |
|||
PO-279 | Ablation of liver FXR results in an increased colonic mucus barrier in mice | Saskia van Mil | ![]() |
![]() |
|||
PO-283 | Transcriptomics identifies longitudinal biomarker gene signatures of NASH fibrosis regressors | Christina Ebert | ![]() |
![]() |
|||
PO-299 | Clinical and radiological characterisation of Polycystic Liver Disease | Benjamin Giles | ![]() |
![]() |
|||
PO-301 | Artificial Intelligence in medical imaging of the liver - a solution for Computed Tomography exam phases recognition | João Martins Cortez Filho | ![]() |
![]() |
|||
PO-302 | Pharmacokinetics, Pharmacodynamics, and toxicology of SZN-043, a hepatocyte-targeted Wnt potentiator, in nonhuman primates | Jay Tibbitts | ![]() |
![]() |
|||
PO-309 | Systemic inflammation promotes liver fibrogenesis and matrix turnover in patients with advanced chronic liver disease | Benedikt Simbrunner | ![]() |
![]() |
|||
PO-310 | Von Willebrand Factor (VWF) propeptide levels are similarly accurate for assessing portal hypertension as compared to VWF antigen | Ida Villesen | ![]() |
![]() |
|||
PO-313 | The prognosis is impaired in NAFLD patients with diabetes despite negative FIB4 1.30 | Jerome Boursier | ![]() |
![]() |
|||
PO-323 | Liver phenotype of adults with alpha-1 antitrypsin deficiency in the UK Biobank and in an international, multi-center cohort | Malin Fromme | ![]() |
![]() |
|||
PO-336 | Differential requirement of RAS-dependent signaling pathways in tumor development and differentiation in murine liver cancer | Carina Rupp | ![]() |
![]() |
|||
PO-337 | Funded referral to a commercial weight loss provider is effective in achieving weight loss in Non-alcoholic fatty liver disease | Iain Hay | ![]() |
![]() |
|||
PO-342 | Improved survival and reduced risk of hospital admissions after 12-weeks of resistance training in patients with cirrhosis - a three year follow-up from randomization | Luise Aamann | ![]() |
![]() |
|||
PO-344 | Immnohistochemical staining of cholangioscopy-directed biopsies of cholangiocarcinoma in Primary Sclerosing Cholangitis | Stephanie Yan | ![]() |
![]() |
|||
PO-345 | Alcoholic foamy degeneration: a singular clinical entity that mimics alcoholic hepatitis and may be distinguished by serum triglyceride levels | Jordi Gratacós-Ginès | ![]() |
![]() |
|||
PO-351 | Liver transplantation for NAFLD cirrhosis : early overall patient survival is good | Franois Villeret | ![]() |
![]() |
|||
PO-353 | Disease recurrence after liver transplantation for NAFLD cirrhosis : just wait | Franois Villeret | ![]() |
![]() |
|||
PO-364 | Waitlist outcomes for alcoholic hepatitis are more favorable than for other candidates with high Model for End-stage Liver Disease score in the current era | Therese Bittermann | ![]() |
![]() |
|||
PO-375 | A profibrotic role for the orphan G-protein coupled receptor 176 during hepatic stellate cell activation | Vincent De Smet | ![]() |
![]() |
|||
PO-376 | Machine learning in primary biliary cholangitis: a novel approach for risk stratification | Alessio Gerussi | ![]() |
![]() |
|||
PO-377 | Risk of multiple drug-drug interactions (DDIs) in HCV patients receiving pangenotypic DAAs (pDAAs): A complex drug interaction scenario first time evaluated in German patients | Frank Tacke | ![]() |
![]() |
|||
PO-381 | relevance of psychosocial biomarkers on therapeutic adherence in patients with non-alcoholic fatty liver disease | Jesús Funuyet-Salas | ![]() |
![]() |
|||
PO-388 | Increased screening, tailored access, linkage to care and treatment for PWUD through a patient centered program | Alessandra Mangia | ![]() |
![]() |
|||
PO-393 | MET642, an FXR agonist with a unique chemotype, demonstrates a safe, sustained profile in a14-day randomized study in healthy subjects | Richard Pencek | ![]() |
![]() |
|||
PO-397 | Novel hepatitis B virus gene expression inhibitor in clinical development | Vadim Bichko | ![]() |
![]() |
|||
PO-404 | 12 weeks treatment of Sofosbuvir/Velpatasvir in HCV negative recipients receiving renal transplantation from HCV positive donors | Ruoyang Chen | ![]() |
![]() |
|||
PO-408 | Circulating HBV RNA correlates with intrahepatic covalently closed circular DNA (cccDNA) transcriptional activity in untreated and NUC-treated chronic hepatitis B (CHB) patients | Barbara Testoni | ![]() |
![]() |
|||
PO-409 | Cause of Death and Cause-Specific Mortality in Primary Liver Cancer: Temporal Trends in a Hepatitis B Virus Endemic Area | Bo Hyun Kim | ![]() |
![]() |
|||
PO-410 | The inhibition of the YAP-1/CTGF pathway improves chronic biliary fibrosis in the Abcb4-/- model by modulation of hepatic stellate cell physiology | Liangtao Ye | ![]() |
![]() |
|||
PO-418 | Rifaximin and Fecal Microbiota Transplant beneficially modulate gut metagenomic virulence factors in cirrhosis: Analysis of two trials | Jasmohan Bajaj | ![]() |
![]() |
|||
PO-420 | A 3-antigen prophylactic hepatitis B virus vaccine confers rapid onset of protection in young adults, age 18-45, compared to a single-antigen hepatitis B virus vaccine | Francisco Diaz-Mitoma | ![]() |
![]() |
|||
PO-424 | Simplified test and treat protocols for population level screening and elimination of hepatitis B and hepatitis C in Uzbekistan | Rick Dunn | ![]() |
![]() |
|||
PO-425 | Modelling the potential effectiveness of different screening and treatment strategies for hepatitis c during pregnancy in Ukraine | Nadia Hachicha Maalej | ![]() |
![]() |
|||
PO-430 | High probability of reactive HBV-specific CD8 cells after stopping nucleos(t)ide analogue treatment forecast rapid HBsAg decrease in eAg(-) chronic hepatitis B | Julia Peña Asensio | ![]() |
![]() |
|||
PO-433 | Drivers of outcome in compensated alcohol-related cirrhosis: a prospective study | Alexandre Louvet | ![]() |
![]() |
|||
PO-435 | Hyperammoniemia and intrahepatic microcirculation disorders and its correction at the nonalcoholic steatohepatitis patients with initial stages of liver fibrosis | Tatiana Ermolova | ![]() |
![]() |
|||
PO-441 | Low alcohol consumption is associated with a decreased frequency of cirrhosis and hepatocellular carcinoma in a cohort of NAFLD outpatients | Bernardo Stefanini | ![]() |
![]() |
|||
PO-442 | SZN-043, a Hepatocyte-targeted-R-spondin mimetic, stimulates hepatocyte proliferation in an acute alcoholic hepatitis model | Trevor Fisher | ![]() |
![]() |
|||
PO-443 | SZN-043, a hepatocyte targeted R-spondin mimetic, induces hepatocyte proliferation in acute acetaminophen-induced liver injury model | Mehaben Patel | ![]() |
![]() |
|||
PO-445 | ASSOCIATION OF MAFLD WITH MORTALITY IN PARIENTS WITH COVID-19 IN MÉXICO | Martín Uriel Vázquez-Medina | ![]() |
![]() |
|||
PO-453 | The impact of unrestricted access to direct-acting antiviral among 1001 incarcerated hepatitis C virus-infected patients | Yu Jun Wong | ![]() |
![]() |
|||
PO-454 | Application of FIB-4 and NFS in primary care: Over 1/3 of older patients with diabetes meet criteria for high risk of advanced fibrosis with the use of age-specific cutoffs | Kendall Islam | ![]() |
![]() |
|||
PO-460 | Persistent High HBsAg Levels Predict Lower Risk of Hepatocellular Carcinoma in HBeAg-seropositive Chronic Hepatitis B Patients | Hsin-Che Lin | ![]() |
![]() |
|||
PO-468 | Direct antivirals can achieve a cure in all patients with chronic hepatitis C due to genotype 5. A French multicentre study. | Carine Nicolas | ![]() |
![]() |
|||
PO-469 | Study of the effect of the hepatitis D virus on the hepatitis B virus quasispecies in mice models by a next-generation sequencing approach | David Tabernero | ![]() |
![]() |
|||
PO-470 | Restoration of altered bile acid pool prevents the development of nonalcoholic steatohepatitis | Justine Gillard | ![]() |
![]() |
|||
PO-475 | Inactivation of ACSL5, an interacting protein of TM6SF2, results in decreased plasma TG and cholesterol without affecting hepatic lipids | Fei Luo | ![]() |
![]() |
|||
PO-477 | hepatic lpi/gpr55 systemregulates the development of non-alcoholic steatosis and steatohepatitis | Uxía Fernández | ![]() |
![]() |
|||
PO-479 | Inhibition of hepatic p63 reduces the fibrosis in NASH | Marcos F Fondevila | ![]() |
![]() |
|||
PO-482 | Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection | Lisa Danzig | ![]() |
![]() |
|||
PO-485 | Baveno-VI criteria to predict variceal bleeding and liver decompensation in compensated cirrhosis patients | FRANCIS TEH BAN | ![]() |
![]() |
|||
PO-487 | Binge drinking induces an acute release of markers of hepatic fibrogenesis (PRO-C3) | Nikolaj Torp | ![]() |
![]() |
|||
PO-488 | Has the 5-year mortality of patients with alcoholic cirrhosis changed during the last 20 years ? | Edeline Kaze | ![]() |
![]() |
|||
PO-504 | Innovative linkage model to re-engage lost-to-follow-up individuals in the national hepatitis C elimination program of Georgia | Amiran Gamkrelidze | ![]() |
![]() |
|||
PO-511 | Health status perception and patient experience in liver cancer patients participating in Nurse-led Educational Programs | Neus Llarch Alfonso | ![]() |
![]() |
|||
PO-525 | Pooling plasma samples for hepatitis C RNA detection: a strategy to expand access to diagnostics | Federico Garcia | ![]() |
![]() |
|||
PO-526 | Real life kinetics of new HBV markers during treatment of chronic hepatitis D with bulevirtide | CHARLOTTE PRONIER | ![]() |
![]() |
|||
PO-529 | Clinical importance of a new, high-sensitivity HBcrAg assay for monitoring chronic hepatitis B and HBV reactivation | Takako Inoue | ![]() |
![]() |
|||
PO-530 | Chances of renal recovery in liver only transplant recipients who were eligible for simultaneous liver-kidney transplant | Jiawei Cui | ![]() |
![]() |
|||
PO-532 | Clinical outcomes of cirrhotic patients with dysregulated hormones of vascular homeostasis | Lukas Hartl | ![]() |
![]() |
|||
PO-533 | Healthcare restrictions due to COVID-19 impaired liver care, lowered patient satisfaction and increased liver-related mortality | Lukas Hartl | ![]() |
![]() |
|||
PO-534 | Pharmacokinetics of tropifexor, a potent farnesoid X receptor agonist, are similar in subjects with mild, moderate, and severe hepatic impairment: results from a multicentre, open-label, single-dose study | Rowan Stringer | ![]() |
![]() |
|||
PO-537 | Protective effect of GOLM1 on acute liver failure in mice | Linlan Qiao | ![]() |
![]() |
|||
PO-539 | Promoting Hepatitis Virus Screening Test at Worksite in Japan Using Nudge Theory compared with Full Subsidies | Masaaki Korenaga | ![]() |
![]() |
|||
PO-541 | Molecular characterization of HCC in Mongolia delineates unique genomic features | Laura Torrens | ![]() |
![]() |
|||
PO-550 | serpina3c deficiency promotes high-fat diet-induced steatohepatitis through mediating necroptosis via -catenin-foxo1 axis | linglin qian | ![]() |
![]() |
|||
PO-552 | The landscape of mitochondrial dysfunction in circulating leukocytes of patients with acute-on-chronic liver failure is characterized by altered mitochondrial metabolism and structure | Ingrid Zhang | ![]() |
![]() |
|||
PO-560 | Decreasing VWF levels upon NSBB therapy indicate a reduced risk of further decompensation, ACLF and death | Mathias Jachs | ![]() |
![]() |
|||
PO-561 | Recent portal venous system thrombosis associated with Cytomegalovirus disease: results of a multicenter study | Chloé De Broucker | ![]() |
![]() |
|||
PO-565 | A prospective cohort study for the prevalence and screening policy of NAFLD in patients with T2DM in primary care | Roberta Forlano | ![]() |
![]() |
|||
PO-566 | Association between hepatic fat and subclinical vascular disease burden in the general population | Xinting Cai | ![]() |
![]() |
|||
PO-567 | B-cell-mediated fibrogenesis in non-alcoholic steatohepatitis | Anja Moncsek | ![]() |
![]() |
|||
PO-569 | long term prognosis of patients with alcoholic disease or nafld according to metabolic syndrome or alcohol use | Marie DECRAECKER | ![]() |
![]() |
|||
PO-570 | Portal vein recanalization for severe portal hypertension related to chronic non-cirrhotic extrahepatic portal vein obstruction: long term results | Florent Artru | ![]() |
![]() |
|||
PO-573 | TIAM1, a potential synthetic lethal gene and candidate therapeutic target for hepatocellular carcinoma | Chalermsin Permtermsin | ![]() |
![]() |
|||
PO-574 | Pre-transplant AFP 25.5 is associated with a higher risk of HCC recurrence after liver transplantation for patients meeting Milano criteria | Bianca Magro | ![]() |
![]() |
|||
PO-578 | Long-term follow up in patients with hepatitis C virus treated with direct-acting-ativirals agents | Paula Fernández Alvarez | ![]() |
![]() |
|||
PO-580 | Modeling regional variation in the return on investment of VCTE for fatty liver disease (FLD) in the U.S. | Mazen Noureddin | ![]() |
![]() |
|||
PO-591 | Higher number of transarterial treatments might have detrimental effects on the overall survival of patients eventually receiving systemic treatments | Vito Sansone | ![]() |
![]() |
|||
PO-594 | Incidental Cholangiocarcinoma in Liver Transplantation | Nawaz Safdar | ![]() |
![]() |
|||
PO-602 | Persistent perturbation of the circadian clock by chronic hepatitis C virus infection following cure with direct-acting antivirals | Frank Jhling | ![]() |
![]() |
|||
PO-607 | Acamprosate for the treatment of alcohol use disorder may be safer than baclofen in patients with cirrhosis | Luke Tyson | ![]() |
![]() |
|||
PO-608 | Multicellular primary mouse liver spheroids for DILI, NAFLD, NASH and fibrosis studies | Elise Anne van Os | ![]() |
![]() |
|||
PO-611 | Adaptation of hepatitis C virus to efficient infection of mouse hepatocytes | Julie Sheldon | ![]() |
![]() |
|||
PO-614 | Additive Effects of Diabetes and NAFLD on Liver Disease Severity and Clinical Outcomes in the General Population (NASH-CO Study) | Oumarou NABI | ![]() |
![]() |
|||
PO-624 | Transcriptomic profiling of liver sinusoidal endothelial cells during cirrhosis progression reveals stage-specific secretory signature | Jordi Gracia-Sancho | ![]() |
![]() |
|||
PO-626 | assembly dynamics and infection efficacy of hepatitis b virus surface protein exchanges in the eight hepatitis d virus genotypes | Wenshi Wang | ![]() |
![]() |
|||
PO-627 | Hepatic magnesium accumulation upon cyclin M4 (CNNM4) silencing improves NASH | Jorge Simón | ![]() |
![]() |
|||
PO-629 | Multiparametric MRI as non-invasive tool to assess disease activity in autoimmune hepatitis | johannes hartl | ![]() |
![]() |
|||
PO-630 | Undiagnosed obstructive sleep apnoea is a major component in NAFLD quality of life impairment | Wenhao Li | ![]() |
![]() |
|||
PO-632 | Prevalence of hepatic steatosis and advanced fibrosis in patients living with HIV in Germany | Maurice Michel | ![]() |
![]() |
|||
PO-637 | Achieving hepatitis C micro-elimination in prisons through High Intensive Test and Treat (HITT) interventions | Sean Cox | ![]() |
![]() |
|||
PO-640 | Using the copula method to accurately estimate the impact of body mass index and alcohol consumption on liver disease | Lise RETAT | ![]() |
![]() |
|||
PO-649 | Impact of extending DAAs availability in France: a five-year overview (2015-2019) of data from French administrative healthcare databases (SNDS) | Elias Benabadji | ![]() |
![]() |
|||
PO-655 | Depletion of T cells via inducible caspase 9 increases safety of adoptive T-cell therapy against chronic hepatitis B | Alexandre Klopp | ![]() |
![]() |
|||
PO-663 | Pharmacokinetics, safety, and tolerability of multiple-dose CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in healthy Japanese and non-Japanese adults | Ying Ye | ![]() |
![]() |
|||
PO-665 | Transcriptomic analyses reveal variation of liver inflammation across phases of chronic hepatitis B infection | Ricardo Ramirez | ![]() |
![]() |
|||
PO-666 | Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed After HCV SVR | MING-LUN YEH | ![]() |
![]() |
|||
PO-668 | Safety and pharmacokinetics of DUR-928 in hepatic function impaired subjects | Jaymin Shah | ![]() |
![]() |
|||
PO-675 | Increased incidence of respiratory failure with terlipressin use in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure | Florence Wong | ![]() |
![]() |
|||
PO-676 | An episode of detectable serum hepatitis B virus-DNA level does not affect risk of hepatic decompensation among untreated compensated cirrhosis patient with viral load of 2,000 IU/mL | Hye Won lee | ![]() |
![]() |
|||
PO-677 | New mouse model of cholangiocarcinoma arising in the setting of progressive biliary injury and fibrosis | Pinzhu Huang | ![]() |
![]() |
|||
PO-679 | Development and validation of a noninvasive algorithm to predict significant fibrosis in patients with chronic drug-induced liver injury | Dong Ji | ![]() |
![]() |
|||
PO-685 | The benefits of the novel nomenclature of metabolic fatty liver disease | Álvaro Santos-Laso | ![]() |
![]() |
|||
PO-689 | Titer and breadth of anti-hepatitis C virus E2-glycoprotein antibodies in cirrhotic patients after direct antiviral agent therapy | Daniel Sepúlveda-crespo | ![]() |
![]() |
|||
PO-690 | depist C pharma, an innovative outreach HCV screening project in pharmacy for drug users and general population | Andre-Jean Remy | ![]() |
![]() |
|||
PO-692 | HBV induces collagen VI expression by hepatocytes promoting liver fibrosis | Alessia Virzi | ![]() |
![]() |
|||
PO-697 | Incidence of liver and non-liver related events and mortality in a large cohort of HCV cirrhotics with an SVR to DAA: a 5-year single center study | Roberta DAmbrosio | ![]() |
![]() |
|||
PO-698 | Characterizing sensory thresholds and autonomic dysfunction in cirrhotic patients with minimal hepatic encephalopathy | Dalia Rega | ![]() |
![]() |
|||
PO-700 | Farnesoid X receptor alpha ligands inhibit in vitro HDV replication and virion secretion and infectivity | Christophe Ramière | ![]() |
![]() |
|||
PO-707 | Thyroid disease and hepatocellular carcinoma survival. A Danish nationwide cohort study | Linda Skibsted Kornerup | ![]() |
![]() |
|||
PO-709 | Multi-omic analysis unveils biological pathways in peripheral immune system associated to minimal hepatic encephalopathy appearance in cirrhotic patients | Carmina Montoliu | ![]() |
![]() |
|||
PO-711 | Binge Eating Disorder is associated with an unfavourable body mass composition in patients with Non-Alcoholic fatty liver disease | Roberta Forlano | ![]() |
![]() |
|||
PO-712 | fibrinogen-like protein 2 promotes fulminant hepatitis by inducing neutrophil activition and neutrophil extracellular traps formation | jinshang Hu | ![]() |
![]() |
|||
PO-714 | prognostic impacts of the change in muscle mass on patients with cirrhosis | Tae Hyung Kim | ![]() |
![]() |
|||
PO-715 | One-year safety and efficacy of tenofovir alafenamide (TAF) in chronic hepatitis B (CHB): a HEllenic multicenter ReAl-life CLInical Study (HERACLIS TAF) | George Papatheodoridis | ![]() |
![]() |
|||
PO-716 | distinctive alterations of the hepatic unfolded protein response in models of diabetes and non-alcoholic fatty liver disease | Bedair Dewidar | ![]() |
![]() |
|||
PO-717 | Non-invasive tests to predict liver-related events in a single-center cohort of 486 HCV cirrhotic patients treated with DAA | Elisabetta Degasperi | ![]() |
![]() |
|||
PO-718 | Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy | Sam Murray | ![]() |
![]() |
|||
PO-719 | Carriage of CYP2E1rs2070673:A is associated with higher prevalence of nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease | Hong-Lei Ma | ![]() |
![]() |
|||
PO-725 | Effects of empagliflozin and L-ornithine L-aspartate on behaviour, cognitive function, and physical performance in mice with non-alcoholic steatohepatitis | Veronika Prikhodko | ![]() |
![]() |
|||
PO-733 | Pharmacokinetics, safety, and tolerability of CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in participants with hepatic impairment | Kofi Mensah | ![]() |
![]() |
|||
PO-737 | Genetic haemochromatosis, a common disorder but are General Practitioners still unaware? A qualitative study | Geraldine (Gerri) Mortimore | ![]() |
![]() |
|||
PO-739 | Micro-elimination of Hepatitis C in prisons of Punjab, India | Kanudeep Kaur | ![]() |
![]() |
|||
PO-745 | Simulations of HCV vaccine trials reveal opportunities to re-evaluate vaccine efficacy | Harel Dahari | ![]() |
![]() |
|||
PO-750 | Two trans-arterial chemo-embolizations during liver transplantation waiting list and absence of complete radiological response: time for a systemic strategy? | Edoardo Poli | ![]() |
![]() |
|||
PO-751 | M comes first: Impact of initial probe choice on diagnostic performance of vibration controlled transient elastography | Valentin Blank | ![]() |
![]() |
|||
PO-756 | Combination treatments including semaglutide, cilofexor, and/or firsocostat lead to greater improvements in the FibroScan-AST (FAST) score compared with semaglutide alone in patients with non-alcoholic steatohepatitis | Naim Alkhouri | ![]() |
![]() |
|||
PO-757 | Fenofibrate is safe and mitigates increases in serum triglycerides in NASH patients treated with the combination of the ACC inhibitor firsocostat and the FXR agonist cilofexor: A randomized trial | Eric Lawitz | ![]() |
![]() |
|||
PO-767 | Comparison of HBV-related HCC Incidence Between Entecavir and Tenofovir Treated Cohorts: A Population-based Study | Sichan He | ![]() |
![]() |
|||
PO-769 | A novel radiomics signature based on T2WI accurately predicts hepatic inflammation in individuals with biopsy-proven NAFLD: a derivation and independent validation study | Zhong-Wei Chen | ![]() |
![]() |
|||
PO-770 | Real-world evaluation of second line therapy in Primary Biliary Cholangitis: A multicentre nationwide study | Nadir Abbas | ![]() |
![]() |
|||
PO-773 | Frequency and impact of potential multiple drug-drug interactions (DDIs) associated with pangenotypic direct-acting antivirals in patients receiving opioid substitution therapy | Frank Tacke | ![]() |
![]() |
|||
PO-774 | A combination of gapmers and/or siRNA as potential gene therapy strategy against HBV infection: in vitro results. | Maria Francesca Cortese | ![]() |
![]() |
|||
PO-775 | The effectiveness of a community based two-tier risk stratification pathway for non-alcoholic fatty liver disease | Rebecca Harris | ![]() |
![]() |
|||
PO-778 | The FXR-RXR interaction inhibits FXR isoform-specific gene activation in liver cells | Jose Miguel Ramos Pittol | ![]() |
![]() |
|||
PO-785 | RECONVOCC : Can we reconvene chronic hepatitis C patients who were lost to follow-up ? | Frederic Faure | ![]() |
![]() |
|||
PO-787 | Anti-fibrotic potential of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in preclinical models of fibrosis | Jung Kuk Kim | ![]() |
![]() |
|||
PO-793 | Endothelial GATA4 deficiency causes perisinusoidal liver fibrosis by impaired angiocrine signaling | Manuel Winkler | ![]() |
![]() |
|||
PO-797 | Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: A multi-center,prospective clinical study | Guorong Han | ![]() |
![]() |
|||
PO-799 | Response failure to ursodeoxycholic acid treatment in primary biliary cholangitis is associated with a distinct stool and urine secondary bile acid profile | Laura Martinez-Gili | ![]() |
![]() |
|||
PO-811 | Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B | Dong Ji | ![]() |
![]() |
|||
PO-813 | Prognosis of severe HBV reactivation in Western countries: role of the MELD score | Edoardo Poli | ![]() |
![]() |
|||
PO-815 | Efficacy and safety of 8- or 12 weeks of glecaprevir/pibrentasvir in patients with signs of portal hypertension | Robert Brown | ![]() |
![]() |
|||
PO-818 | Transient splenic elastography predicts high-risk esophageal varices in patients with noncirrhotic portal hypertension | Joel Ferreira-Silva | ![]() |
![]() |
|||
PO-819 | Real-world assessment of NAFLD stages using FibroScan in the US population and diabetes subpopulation based on data from NHANES 2017-2018 | Mazen Noureddin | ![]() |
![]() |
|||
PO-820 | Viral factors and host response in chronic HDV infection | Ester Garcia-Pras | ![]() |
![]() |
|||
PO-821 | Usefulness of FIB-4 as a screening test for chronic liver disease in a university hospital | Victor de Ledinghen | ![]() |
![]() |
|||
PO-824 | Preliminary On-Treatment Data From a Phase 2 Study Evaluating VIR-2218 in Combination With Pegylated InterferonAlfa-2a in Patients With Chronic Hepatitis B Infection | Wendy Re | ![]() |
![]() |
|||
PO-825 | Use of machine learning to develop a NAFLD screening tool using demographic, clinical and FibroScan data from the NHANES 2017-2018 database | Birol Emir | ![]() |
![]() |
|||
PO-831 | Liver related and extrahepatic events in patients with nonalcoholic fatty liver disease: a competing risk analysis | Grazia Pennisi | ![]() |
![]() |
|||
PO-832 | Prevalence of steatosis and fibrosis in individuals with high-alcohol consumption assessed by FibroScan: real-world cohort study from the US population | Naim Alkhouri | ![]() |
![]() |
|||
PO-835 | Safety of 11,043 paracentesis in patients with liver cirrhosis with and without anticoagulant treatment. Large, retrospective, unicentric study. | Jordi Vives Moreno | ![]() |
![]() |
|||
PO-836 | Patients with elevated Fibrosis-4 Index or NAFLD Fibrosis Score have higher rates of cardiovascular events: a post-hoc analysis from two large, randomised statin clinical trials in 18 814 patients | Frank Tacke | ![]() |
![]() |
|||
PO-838 | Combination of an acetyl-CoA carboxylase inhibitor and fibroblast growth factor 19 reduced tissue triglyceride content and fibrosis in human precision-cut liver slices | WEN-WEI TSAI | ![]() |
![]() |
|||
PO-841 | Elevated donor-derived cell-free DNA during subclinical T-cell mediated rejection after liver transplantation | Anna Katharina Baumann | ![]() |
![]() |
|||
PO-846 | Chronic Hepatitis B inflammation gives rise to a novel macrophage population in the human liver | Juan Diego Sanchez | ![]() |
![]() |
|||
PO-849 | TREATMENT OF NASH CIRRHOTICS WITH RESMETIROM IN PHASE 3 MAESTRO-NAFLD-1 NASH STUDY OPEN LABEL ARM: EFFECTS ON BIOMARKERS AND IMAGING | Stephen Harrison | ![]() |
![]() |
|||
PO-851 | Study on multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in animal model of NASH | Jung Kuk Kim | ![]() |
![]() |
|||
PO-852 | Identification of novel host factors in the patho-biology of Hepatitis B Virus (HBV) infection | Collins Oduor Owino | ![]() |
![]() |
|||
PO-853 | A novel therapeutic vaccine achieves functional cure in a mouse model of chronic hepatitis B | Renae Walsh | ![]() |
![]() |
|||
PO-855 | Potential effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in preclinical model of cholestatic liver disease | Jung Kuk Kim | ![]() |
![]() |
|||
PO-857 | Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma | Won-Mook Choi | ![]() |
![]() |
|||
PO-860 | Hepatolithiasis is a frequent and prognostic finding in patients with primary sclerosing cholangitis | Bellal Jubran | ![]() |
![]() |
|||
PO-861 | Exploring host liver responses to Hepatitis B Virus at single cell resolution | Balakrishnan Chakrapani Narmada | ![]() |
![]() |
|||
PO-862 | Mortality risk following HCV cure among people with HIV coinfection | Naveed Janjua | ![]() |
![]() |
|||
PO-864 | Further analysis of simvastatin safety trial in patients with decompensated cirrhosis provides promising information about improving liver function and reducing cirrhosis severity | Alberto Muñoz | ![]() |
![]() |
|||
PO-866 | Comparing traditional machine learning and deep learning models to Fibrosis-4 index in the prediction of non-alcoholic fatty liver disease-associated liver fibrosis | Devon Y. Chang | ![]() |
![]() |
|||
PO-872 | Circulating B-cell activating factor of the tumour necrosis family (BAFF) and interleukin 21 levels predict treatment response in patients with autoimmune hepatitis | Maaike Biewenga | ![]() |
![]() |
|||
PO-881 | Gender differences in microRNAs profile in HIV patients after HCV eradication with DAAs: potential biased consequences | Daniel Valle Millares | ![]() |
![]() |
|||
PO-889 | Digital pathology with artificial intelligence analyses reveal new dynamics of treatment-induced fibrosis regression in nonalcoholic steatohepatitis | Nikolai Naoumov | ![]() |
![]() |
|||
PO-891 | An innovative treatment for Primary Hyperoxaluria Type 1 based on specific gene correction and hepatic direct cell reprogramming | Virginia Nieto-Romero | ![]() |
![]() |
|||
PO-895 | cell cycle-regulatory genetic aberrations and their prognostic implications in early-stage hepatocellular carcinomas | Jihyun An | ![]() |
![]() |
|||
PO-896 | Stimulation of Mucosal-associated invariant T (MAIT) cells by human serum derived from peripheral and portal blood | Martin LETT | ![]() |
![]() |
|||
PO-899 | Deletion of Mcpip1 in Mcpip1fl/flAlbCre mice recapitulates the phenotype of human primary biliary cholangitis | Jerzy Kotlinowski | ![]() |
![]() |
|||
PO-903 | cholangiopathy-related necroptotic cell death recapitulated in human cholangiocyte organoids for screening novel drug targets | Shaojun Shi | ![]() |
![]() |
|||
PO-908 | diagnostic accuracy of dried blood spot and plasma separation card samples for testing hepatitis c virus rna | Agnes Malobela | ![]() |
![]() |
|||
PO-915 | METABOLIC dysfunction associated FATTY LIVER disease and adverse clinical outcomes in patients with CHRONIC HEPATITIS B | Laurens Van Kleef | ![]() |
![]() |
|||
PO-916 | Nonalcoholic fatty liver disease cardiovascular risk by metabolic subtype | David Fernández | ![]() |
![]() |
|||
PO-918 | Low myocardial mechano-energetic efficiency is an independent predictor of prognosis in patients with advanced chronic liver disease | Maurizio Cesari | ![]() |
![]() |
|||
PO-919 | Comparative diagnostic accuracy of blood-based biomarkers for diagnosing NASH: phase 1 results of the LITMUS project | Yasaman Vali | ![]() |
![]() |
|||
PO-920 | immuno-responsive classification of hepatocellular carcinomas as a potential surrogate for precision immuno-oncology | Jihyun An | ![]() |
![]() |
|||
PO-921 | PIVKA-II levels predict hepatocellular carcinoma development in caucasian HCV cirrhotic patients treated with DAAs | Elisabetta Degasperi | ![]() |
![]() |
|||
PO-922 | a novel score to risk stratify and optimize use of liver graft among patients with grade 3 acute on chronic liver failure | ASHWANI SINGAL | ![]() |
![]() |
|||
PO-932 | Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according with the new proposed classification | Maurizio Cesari | ![]() |
![]() |
|||
PO-935 | Liver transplantation for severe alcoholic hepatitis: a multicentre Italian study | Giacomo Germani | ![]() |
![]() |
|||
PO-938 | Therapeutic targeting of integrin alpha v beta 1 in liver fibrosis | Emma Shepherd | ![]() |
![]() |
|||
PO-941 | Independent validation of Agile 4: novel FibroScan based score for the diagnosis of cirrhosis in patients with non-alcoholic fatty liver disease | Jerome Boursier | ![]() |
![]() |
|||
PO-942 | Discovery and Characterization of EDP-721, a Novel Hepatitis B Virus RNA Destabilizer | Michael Vaine | ![]() |
![]() |
|||
PO-944 | Prognostic value of FibroScan based Agile 3 and Agile 4 scores in patients with non-alcoholic fatty liver disease | Jerome Boursier | ![]() |
![]() |
|||
PO-947 | Immunogenetic diversity predicts viral control in chronic HBV (CHB) patients after discontinuation of direct antiviral treatment | Tuefferd Marianne | ![]() |
![]() |
|||
PO-950 | A serum metabolic fingerprint may predict advanced fibrosis due to NAFLD in a cohort of diabetic patients | Roberta Forlano | ![]() |
![]() |
|||
PO-951 | High rates of hidden HCV infections among hospitalized patients aged 55-85 | Alessandra Mangia | ![]() |
![]() |
|||
PO-955 | Cost and effectiveness of treatment at Day 1 (Rapid Start) for hepatitis C and screening intensification in high-risk populations (T&T strategy) in France | Elias Benabadji | ![]() |
![]() |
|||
PO-968 | Terlipressin improves renal replacement therapy-free survival in hepatorenal syndrome type 1 | Juan Carlos Q. Velez | ![]() |
![]() |
|||
PO-969 | Successful implementation of a weight loss intervention pathway for non-alcoholic fatty liver disease patients by advanced practice hepatology providers with obesity training | Vicki Shah | ![]() |
![]() |
|||
PO-974 | Evaluation of cardiac function in cirrhosis across different prognostic stages; A focus on plasma biomarkers of fibrosis | Jolanta Zuwa&322;a-Jagie&322;&322;o | ![]() |
![]() |
|||
PO-975 | long-term effect of hcv eradication with direct acting antiviral (daas) therapy on egyptian patients with mixed cryglobulinemias(mc) | Mohamed Elnadry | ![]() |
![]() |
|||
PO-980 | Incidence rates of hepatobiliary outcomes among patients with non-alcoholic steatohepatitis based on fibrosis-4 score severity at baseline | Christine Coco | ![]() |
![]() |
|||
PO-981 | Aldafermin reduces hydrophobic bile acids in a 24-week, randomized, double-blind, placebo-controlled, multicenter study in patients with nonalcoholic steatohepatitis | Arun Sanyal | ![]() |
![]() |
|||
PO-982 | Development of a novel rat bioreactor to facilitate manufacture of human hepatocyte cell therapies for the treatment of patients with severe liver diseases | Ray Hickey | ![]() |
![]() |
|||
PO-983 | Concordance of SVR 4-12-24 timepoints in an era of reduced sustained virologic response (SVR) determination | Kyle Hammond | ![]() |
![]() |
|||
PO-984 | Hepatopulmonary Syndrome is related with the Development of Acute-on Chronic Liver Failure and Poor prognosis in Cirrhotic patients. | Han Seul Ki | ![]() |
![]() |
|||
PO-985 | The liver fibroinflammatory marker cT1 is reduced with aldafermin therapy in a randomized, double-blind, placebo-controlled, multicenter study in patients with nonalcoholic steatohepatitis | Lei Ling | ![]() |
![]() |
|||
PO-987 | Alfosbuvir (SH229) plus daclatasvir for treatment of chronic hepatitis C virus infection in China: a single-arm, open-label, phase 3 study | Xian Zhang | ![]() |
![]() |
|||
PO-990 | Tenofovir Alafenamide Used Throughout Pregnancy in Chinese Active Chronic Hepatitis B Mothers: A Multicenter Prospective Study | Qing-Lei Zeng | ![]() |
![]() |
|||
PO-994 | Hepatic fat loss in cirrhosis: Evaluation of malnutrition using MRI proton density fat fraction (MRI-PDFF) | ATSUSHI NAKAMURA | ![]() |
![]() |
|||
PO-1000 | Association of Vitamin D receptors CdX-2 polymorphism and related haplotypes in patients with chronic hepatitis B infection in the inactive carrier and chronic hepatitis phases: a case-control study | Prooksa Ananchuensook | ![]() |
![]() |
|||
PO-1001 | External Validation of the FAST Score as a Predictor of Fibrotic NASH in a Large Cohort of U.S. Adults with Biopsy-Proven NAFLD | Prido Polanco | ![]() |
![]() |
|||
PO-1004 | safety, tolerability and pharmacokinetics (pk) of single and multiple doses of alg-010133, an s-antigen transport inhibiting oligonucleotide polymer (stops) for the treatment of chronic hepatitis b | Edward Gane | ![]() |
![]() |
|||
PO-1007 | A comprehensive HBsAg-positive patient centered screening strategy targeting microelimination of Hepatitis C virus in Chongqing,China | DACHUAN CAI | ![]() |
![]() |
|||
PO-1010 | Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice: CARDIO-SOR study. | Lorena Carballo-Folgoso | ![]() |
![]() |
|||
PO-1017 | Non-invasive scores of hepatic fibrosis in autoimmune hepatitis | Marco Ferronato | ![]() |
![]() |
|||
PO-1020 | Individualized polygenic risk score identifies NASH in the eastern Asia region: a derivation and validation study | Feng Gao | ![]() |
![]() |
|||
PO-1023 | Intravital dynamic and correlative imaging reveals the mechanism of canalicular bile flux | Nachiket Vartak | ![]() |
![]() |
|||
PO-1026 | Serum nuclear magnetic resonance metabolomic signature can discriminate between immunoglobulin G4-related sclerosing cholangitis and primary sclerosing cholangitis | Emmanuel Selvaraj | ![]() |
![]() |
|||
PO-1027 | A low carbohydrate diet partially prevents the hepatic phenotype of hepatocyte OGT-deficient mice. | Lucia Parlati | ![]() |
![]() |
|||
PO-1029 | Acute hepatitis C virus infection: A prospective ten years observational study of HCV-mono- and HCV/HIV-coinfected patients | Christiana Graf | ![]() |
![]() |
|||
PO-1030 | Associations of Hydroxysteroid 17-Beta Dehydrogenase 13 Variants with Liver Histology In Chinese Patients with Metabolic-Associated Fatty Liver Disease | Wen-Yue Liu | ![]() |
![]() |
|||
PO-1032 | Impact of hyponatremia on morbidity, mortality and resource utilization in portal hypertensive ascites: a nationwide analysis | JOSEPH ALUKAL | ![]() |
![]() |
|||
PO-1035 | A novel approach to age cohort screening for hepatitis C in the primary care setting of a large urban health care setting with linkage to care | David Bernstein | ![]() |
![]() |
|||
PO-1037 | Inhibition of ATG3 ameliorates liver steatosis and improves fatty acid metabolism | Eva María Novoa Deaño | ![]() |
![]() |
|||
PO-1038 | A scoring model to predict mortality in hospitalized patients with decompensated cirrhosis and hyponatremia | JOSEPH ALUKAL | ![]() |
![]() |
|||
PO-1040 | The natural history of advanced chronic liver disease defined by transient elastography | Jessica Shearer | ![]() |
![]() |
|||
PO-1045 | A Double Blind, Randomised, Placebo-Controlled Study To Assess Safety and Tolerability of Oral Enterosorbent Yaq-001 In Cirrhotic Patients (CARBALIVE Consortium) | Jane Macnaughtan | ![]() |
![]() |
|||
PO-1047 | Jaundice detection by deep convolutional neural network using smartphone images | Tung-Hung Su | ![]() |
![]() |
|||
PO-1051 | Systemic and hepatic endothelial cell activation biomarkers expression are associated with inflammation and disease progression in patients with cirrhosis | Jelte Schaapman | ![]() |
![]() |
|||
PO-1056 | Biomarker screening strategies to identify at-risk NASH cases for clinical trial recruitment in NAFLD | Yasaman Vali | ![]() |
![]() |
|||
PO-1064 | Emergency room care is essential in improving outcomes of decompensated cirrhosis patients: A Canadian experience | Abdel-Aziz Shaheen | ![]() |
![]() |
|||
PO-1069 | The AST/AST ratio: a second line component of the hepatic fibrosis screening by FIB-4 calculated automatically in 131,861 subjects. | DENIS OUZAN | ![]() |
![]() |
|||
PO-1074 | The FGF19 analogue aldafermin enriches the lactate-consuming, bile acid-sensitive commensal microbe Veillonella in patients with primary sclerosing cholangitis | Lei Ling | ![]() |
![]() |
|||
PO-1082 | Atherosclerotic cardiovascular risk assessment in a 24-week, randomized, double-blind, placebo-controlled study of aldafermin | Nadege T. Gunn | ![]() |
![]() |
|||
PO-1090 | The impacts of gender differences in muscle mass and adipose tissue on the outcomes of hepatocellular carcinoma after surgical resection | Pei-Chang Lee | ![]() |
![]() |
|||
PO-1091 | CHESS criteria for screening and monitoring of varices needing treatment: an international multicenter study | Chuan Liu | ![]() |
![]() |
|||
PO-1094 | Timing of endoscopy for acute variceal bleeding in patients with cirrhosis (CHESS1905): a nationwide cohort study | Yifei Huang | ![]() |
![]() |
|||
PO-1099 | The alarming impact of COVID-19 pandemic on alcohol-related liver disease: a population-based Canadian study | Abdel-Aziz Shaheen | ![]() |
![]() |
|||
PO-1102 | Epidemiology of spontaneous bacterial peritonitis and bacterascites in patients with cirrhosis in Queensland, Australia from 2008-2017 | Amy Johnson | ![]() |
![]() |
|||
PO-1103 | In-hospital mortality after surgery in patients with liver cirrhosis: A nationwide study of 1,662,887 patients | Jeong-Ju Yoo | ![]() |
![]() |
|||
PO-1106 | Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with NAFLD | Yu-Jie Zhou | ![]() |
![]() |
|||
PO-1107 | Acute liver injury among patients with COVID-19 in a tertiary hospital | Henry Winston Li | ![]() |
![]() |
|||
PO-1112 | Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 Study of FASN Inhibitor TVB-2640 | MARIE OFARRELL | ![]() |
![]() |
|||
PO-1115 | Clinical aspect of coronavirus disease 2019 (COIVD-19) on HBV infected patients in term of Health Insurance Review & Assessment service data | Young Kul Jung | ![]() |
![]() |
|||
PO-1118 | Metabolic reprogramming in a c-Myc/h-Ras transgenic mouse model of hepatocellular carcinoma | Marina Serra | ![]() |
![]() |
|||
PO-1119 | Anti-apoptotic effect of mycophenolate mofetil in human hepatocytes cultures | Razvan Iacob | ![]() |
![]() |
|||
PO-1124 | Hepatocellular carcinoma recurrence after direct-acting antiviral therapy for hepatitis C virus. A systematic review and meta-analysis. | Leonardo Frazzoni | ![]() |
![]() |
|||
PO-1125 | Using the Enhanced Liver Fibrosis test in Primary Care: A practical pathway to prioritise patients with fibrosis in Fatty Liver Disease | Alexander Hinkson | ![]() |
![]() |
|||
PO-1126 | Patients with MELD exceptions have higher access to liver transplantation and lower waiting list mortality: the Swiss nationwide experience | Melisa Dirchwolf | ![]() |
![]() |
|||
PO-1133 | Post-transplant outcomes of previously refused liver grafts: a 10-years nationwide experience | Chiara Becchetti | ![]() |
![]() |
|||
PO-1142 | Duration of response and outcomes in advanced hepatocelluar carcinoma patients with objective response to sorafenib: role of sub sequent treatment. | Kuo-Wei Huang | ![]() |
![]() |
|||
PO-1146 | Metamizole intake is associated with acute kidney injury in patients with decompensated liver cirrhosis | Tammo Tergast | ![]() |
![]() |
|||
PO-1150 | The hepatic IKK-NFkB axis induces liver steatosis by increasing de novo lipogenesis and cholesterol synthesis | Andries Heida | ![]() |
![]() |
|||
PO-1151 | Stratifying the risk of variceal bleeding by non-invasive tools in patients with compensated advanced chronic liver disease: A decision curve analysis | Sanchit Sharma | ![]() |
![]() |
|||
PO-1152 | Risk stratification based on liver stiffness and platelets for decompensation events in patients with compensated cirrhosis | Ruiling He | ![]() |
![]() |
|||
PO-1153 | Weight variations and level of estrogen exposure predict the evolution of hepatocellular adenomas | Alix Demory | ![]() |
![]() |
|||
PO-1154 | Influence of human fecal bacterias secretome in the maturation and function of the liver | Joana I. Almeida | ![]() |
![]() |
|||
PO-1158 | Baseline characteristics of a large multi-site chronic HBV electronic health record-based cohort in the UK | Cori Campbell | ![]() |
![]() |
|||
PO-1161 | Impact of INFECTIONS on the post-operative survival of ACUTE-ON-CHRONIC LIVER FAILURE patients undergoing LIVER TRANSPLANTATION | Elina Lam | ![]() |
![]() |
|||
PO-1164 | External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population | Hanne strm | ![]() |
![]() |
|||
PO-1165 | Cirrhocare - a pilot study of digital home-monitoring of advanced cirrhosis to determine feasibility and utility to diagnose new decompensation events. | Konstantin Kazankov | ![]() |
![]() |
|||
PO-1168 | Graft survival following retransplantation - a large single centre retrospective analysis | James Morgan | ![]() |
![]() |
|||
PO-1169 | Changes in the Profile and Outcomes of Paediatric Liver Transplantation in the United States | Carey Escheik | ![]() |
![]() |
|||
PO-1176 | Hepatitis C virus eradication improves cognition in patients with and without cirrhosis: results from a real-life prospective study. | Luis Ibáñez-Samaniego | ![]() |
![]() |
|||
PO-1185 | Magnesium homeostasis by Cyclin M4: a novel therapeutic mechanism in Acetaminophen-induced liver damage | Irene Gonzalez Recio | ![]() |
![]() |
|||
PO-1186 | Detection of active hepatitis C by two-step point-of-care based strategy and linkage to care among excluded people using a mobile unit in Madrid, Spain. | Pablo Ryan | ![]() |
![]() |
|||
PO-1193 | Lifestyle changes after cured Hepatitis C patients and adherence of a nurse-led liver cancer screening program | Núria Granel | ![]() |
![]() |
|||
PO-1195 | PNPLA3 and SERPINA1 are associated with liver disease severity in an uned fatty liver disease cohort | Lorenz Balcar | ![]() |
![]() |
|||
PO-1196 | ALG-125755, a Small Interfering RNA (siRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model | Jin Hong | ![]() |
![]() |
|||
PO-1198 | Efficacy Signals Of 4-Week Oral DUR-928 in NASH Subjects | WeiQi Lin | ![]() |
![]() |
|||
PO-1202 | Curriculum-based education in NAFLD/NASH improves knowledge, competence, and confidence among gastroenterologists | Shari Dermer | ![]() |
![]() |
|||
PO-1205 | Metabolic dysfunction-associated fatty liver disease (MAFLD) rather a bystander than a driver of mortality | Georg Semmler | ![]() |
![]() |
|||
PO-1207 | Selective hypoxia-inducible-factor stabilisation alleviates hepatocellular steatosis and ballooning in a rodent model of 70 liver resection | Samuele Iesari | ![]() |
![]() |
|||
PO-1215 | Cell specific roles of MLKL in alcohol-assoicated liver disease | Xiaoqin Wu | ![]() |
![]() |
|||
PO-1217 | Hepatocellular carcinoma in patients with NASH is associated with a specific pattern of muscle fat infiltration: a first-order radiomics study based on MRI-PDFF | Maxime Nachit | ![]() |
![]() |
|||
PO-1220 | PNPLA3 and TM6SF2 are neither associated with decreased cardiovascular nor increased liver-related mortality in the general population | Lorenz Balcar | ![]() |
![]() |
|||
PO-1221 | Importance of a clinical pharmacist specialized in hepatitis C treatment for the management of potential drug-drug interactions in a multidisciplinary ECHO hepatitis C expert team | Yaroslav Filippov | ![]() |
![]() |
|||
PO-1222 | PNPLA3-associated cirrhosis: HSD17B13 and MBOAT7 variants as modulators of chronic liver injury. | Matthias Reichert | ![]() |
![]() |
|||
PO-1227 | Poor Awareness of Non Alcoholic Fatty Liver Disease (NAFLD) Among Adults in the United States | Carey Escheik | ![]() |
![]() |
|||
PO-1230 | FIB-4 improves LSM-based prediction of clinical decompensation in overweight or obese patients with compensated advanced chronic liver disease | Yuly Paulin Mendoza | ![]() |
![]() |
|||
PO-1235 | Proteomics Signature of Advanced Fibrosis in Non-alcoholic Steatohepatitis (NASH) using Data-independent Acquisition (DIA) Mass Spectrometry | Carey Escheik | ![]() |
![]() |
|||
PO-1236 | Beta-blockers to prevent decompensation of cirrhosis: an emulation of the PREDESCI trial | Elliot Tapper | ![]() |
![]() |
|||
PO-1238 | Natural history and clinical impact of non-neoplastic portal vein thrombosis in cirrhotics with hepatocellular carcinoma | SARAH SHALABY | ![]() |
![]() |
|||
PO-1240 | Pharmacokinetics of ATI-2173, a novel active site polymerase inhibitor nucleotide (ASPIN), in a Phase 1b clinical trial | Katherine Squires | ![]() |
![]() |
|||
PO-1243 | Direct oral anticoagulants (DOACs) for off-label use in patients with Budd Chiari Syndrome (BCS) | Georg Semmler | ![]() |
![]() |
|||
PO-1244 | The prevalence of PSYCHIATRIC comorbidities in WILSONS DISEASE | Merjem Begic | ![]() |
![]() |
|||
PO-1247 | New onset steatosis but not persistent steatosis prevents hepatic fibrosis improvement after viral eradication by direct-acting antiviral therapy (DAAs) in patients with chronic hepatitis C: evaluation by CAP and LSM | Annalisa Cespiati | ![]() |
![]() |
|||
PO-1249 | Safety of direct oral anticoagulants (DOACs) in patients with advanced liver disease | Georg Semmler | ![]() |
![]() |
|||
PO-1251 | Phase 1 results for ATI-2173, a novel active site polymerase inhibitor nucleotide (ASPIN), in HBV-infected subjects | Douglas Mayers | ![]() |
![]() |
|||
PO-1257 | Combination drug interactions of hepatitis B virus ( HBV) small interfering RNA (siRNA) and antisense oligonucleotides (ASO) in vitro and in vivo | Hua Tan | ![]() |
![]() |
|||
PO-1263 | Impact of metabolic syndrome and non-alcoholic fatty liver disease in outcomes and tolerance after percutaneous multibipolar radiofrequency ablation for early hepatocellular carcinoma | Thi Thu Nga Nguyen | ![]() |
![]() |
|||
PO-1270 | Safety and efficacy of switching to besifovir dipivoxil maleate in virologically-suppressed chronic hepatitis B patients with tenofovir disoproxil fumarate: 24-week interim analysis | Hyung Joon Yim | ![]() |
![]() |
|||
PO-1278 | Does continuing anticoagulation increase the risk of bleeding during variceal band ligation in patients with portal hypertension? A meta-analysis and systematic review | Mark Muthiah | ![]() |
![]() |
|||
PO-1285 | An integrated analysis of long-term clinical safety in maralixibat-treated participants with Alagille syndrome | Rakesh K Raman | ![]() |
![]() |
|||
PO-1286 | No emergent core inhibitor resistance in patients with chronic hepatitis B virus infection treated with Vebicorvir in combination with a nucleos(t)ide reverse transcriptase inhibitor | Gregory Suess | ![]() |
![]() |
|||
PO-1289 | Cirrhosis regression based on both Enhanced Liver Fibrosis (ELF) and Fibrotest after direct-acting hepatitis C therapeutics corresponded to a lower incidence rate of hepatocellular carcinoma (HCC) below the cost-effective threshold for surveillance | Winston Dunn | ![]() |
![]() |
|||
PO-1294 | Implementation of a national registry for patients with primary biliary cholangitis (PBC): The German PBC cohort | Johannes Wiegand | ![]() |
![]() |
|||
PO-1296 | Pruritus, anxiety, and depression in patients with nonalcoholic fatty liver disease | Albrecht Boehlig | ![]() |
![]() |
|||
PO-1304 | Targeting tumor-initiating cells and compensatory YAP pathway activation to overcome sorafenib-induced resistance in hepatocellular carcinoma | Darko Castven | ![]() |
![]() |
|||
PO-1305 | Mechanism of Action of Hepatitis B Virus S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPSTM) Molecules. | C. Cheng Kao | ![]() |
![]() |
|||
PO-1307 | High rate of early HCV reinfection among PWID with high-risk practices and re-treatment efficacy | Sabela Lens | ![]() |
![]() |
|||
PO-1309 | Alanine aminotransferase flares and seroclearance in chronic hepatitis B virus patients | Shahed Iqbal | ![]() |
![]() |
|||
PO-1311 | The peri-ductular CCL24 rich niche promotes bile duct fibrosis related liver damage in primary sclerosing cholangitis | Aharon Aharon | ![]() |
![]() |
|||
PO-1312 | The impact of betablocker treatment on cancer prognosis in patients with advanced hepatocellular carcinoma receiving sorafenib treatment | Lorenz Balcar | ![]() |
![]() |
|||
PO-1314 | The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial | Reshma Shringarpure | ![]() |
![]() |
|||
PO-1316 | Factor VIII/protein C ratio independently predicts liver-related events but does not reflect the hypercoagulable state in patients with advanced chronic liver disease | Lorenz Balcar | ![]() |
![]() |
|||
PO-1330 | Performance of screening strategies for primary prophylaxis of variceal bleeding in patients with compensated cirrhosis: a cost-effectiveness analysis | Shanshan Lin | ![]() |
![]() |
|||
PO-1333 | Osteopontin expression identifies a subset of macrophages distinct from Kupffer Cells in the fatty liver | Anneleen Remmerie | ![]() |
![]() |
|||
PO-1334 | Mild alcohol consumption and risk for cardiovascular disease in patients with non-alcoholic steatohepatitis: data from a multicenter observational study. | Savvoula Savvidou | ![]() |
![]() |
|||
PO-1335 | Metabolomic predictive models in the diagnosis of drug-induced liver injury | Daniel E. Di Zeo-Sánchez | ![]() |
![]() |
|||
PO-1336 | The liver fibrosis marker PRO-C3 increases with fibrosis stage and is neither elevated in diabetics without liver disease nor in healthy obese subjects | Diana Julie Leeming | ![]() |
![]() |
|||
PO-1339 | Impact of the COVID-19 pandemic on hepatitis C virus screening in drug treatment settings in England and implications for testing protocols | Shayon Salehi | ![]() |
![]() |
|||
PO-1340 | Association between chronic hepatitis B infection and COVID-19: A nationwide case-control study | Seong Hee Kang | ![]() |
![]() |
|||
PO-1341 | Active search to retrieve lost-to follow-up HCV patients (RELINK-C strategy): health and economic value | Raquel Domínguez-Hernández | ![]() |
![]() |
|||
PO-1346 | Double negative T cells mediate CD39-dependent protection in hepatic ischemia and reperfusion injury | Hua Jin | ![]() |
![]() |
|||
PO-1351 | Preliminary experience on safety of cabozantinib in recurrent hepatocellular carcinoma after liver transplantation. A case series | federica invernizzi | ![]() |
![]() |
|||
PO-1352 | Study on the mechanism of chemokine CCL21 mediating IRBIT in the malignant biological behavior of liver cancer | Jianhong Ding | ![]() |
![]() |
|||
PO-1353 | Randomized controlled study:investigation of the effcet of exercise on liver function tests,fatigue and quality of life in patients with liver cirrhosis | Hlya Keskin | ![]() |
![]() |
|||
PO-1354 | Wilson Disease is associated with prevalent neuropsychiatric comorbidity | Eva-Doreen Pfister | ![]() |
![]() |
|||
PO-1356 | Hypoxia-induced liver angiogenesis rescues survival upon small for size hepatectomy in mice | Maxime De Rudder | ![]() |
![]() |
|||
PO-1357 | Role of ASCT2 and KGA for ammonia-induced astrocyte senescence | Olivia Knappe | ![]() |
![]() |
|||
PO-1359 | Anti-oxidant, anti-inflammatory, and anti-fibrotic properties of triterpenic acids and phenylpropanoids on in vitro models of non-alcoholic steatohepatitis | Noel Salvoza | ![]() |
![]() |
|||
PO-1364 | Is it the scale (rather than the nature) of the inflammatory response in autoimmune hepatitis that determines treatment response? | Jessica Dyson | ![]() |
![]() |
|||
PO-1369 | Non-alcoholic fatty liver disease in a rodent model of bariatric surgery with different bypass lengths | Paula Richwien | ![]() |
![]() |
|||
PO-1374 | Optimizing diagnostic algorithms to advance HCV elimination in Italy: A cost effectiveness evaluation | Loreta A. Kondili | ![]() |
![]() |
|||
PO-1375 | Alcohol consumption and the interest in reducing it among patients with alcohol-related liver disease: a national health survey | Anna Emilie Kann | ![]() |
![]() |
|||
PO-1379 | Enrichment of CXCR3CD27CD161 NK cells in autoimmune and drug induced liver injury | Amber Bozward | ![]() |
![]() |
|||
PO-1385 | Risk of Hepatitis B Virus Reactivation in Patients Treated with Immunotherapy for Anti-cancer Treatment | Sun Yoo | ![]() |
![]() |
|||
PO-1386 | Capsid assembly modulator ALG-000111 and its prodrug ALG-000286 display excellent in vitro and in vivo antiviral activity | Yannick Debing | ![]() |
![]() |
|||
PO-1387 | Plasma Soluble CD14 predicted development of hospital acquired infection in decompensated cirrhosis patients from the ATTIRE trial | Louise China | ![]() |
![]() |
|||
PO-1389 | Effect of corticosteroids in the outcome of drug-induced liver injury: a propensity score matched study | Hao Niu | ![]() |
![]() |
|||
PO-1397 | Community-based linkage to care program targeting HCV elimination - Estalishment of a model towards HCV elimination in china. | Ming Li | ![]() |
![]() |
|||
PO-1404 | Metabolomic changes in HIV/HCV coinfected patients after DAAs therapy | Óscar Brochado | ![]() |
![]() |
|||
PO-1415 | Usefulness of dried blood spot samples for HCV genotyping to inform retreatment after recurrent viremia in people who inject drugs in the real world | Elisa Martró | ![]() |
![]() |
|||
PO-1416 | Pharmacokinetics and safety of JNJ-73763989, an RNA interference therapy for hepatitis B virus, in moderately hepatically impaired participants | Thomas Kakuda | ![]() |
![]() |
|||
PO-1418 | Risk of primary biliary cholangitis in first degree relatives: a prospective cohort study | johannes hartl | ![]() |
![]() |
|||
PO-1419 | First real-life experiences with 2 mg bulevirtide for the treatment of hepatitis delta - data from a tertiary reference centre in Germany | Caroline Zllner | ![]() |
![]() |
|||
PO-1420 | Molecular markers of response to anti-pd1 therapy in advanced hepatocellular carcinoma | Philipp Haber | ![]() |
![]() |
|||
PO-1421 | The 2010 HIV outbreak among people who inject drugs in Athens, Greece could have been prevented if the undetected 2009 HCV outbreak had been detected: A mathematical modeling study | Ilias Gountas | ![]() |
![]() |
|||
PO-1422 | Longitudinal monitoring of bioengineered whole liver constructs using a novel perfusion bioreactor | Sara Campinoti | ![]() |
![]() |
|||
PO-1426 | A discrete choice experiment about patients and clinicians preferences for the meet-test-treat approach to HCV management | Patrizio Pasqualetti | ![]() |
![]() |
|||
PO-1428 | The measurement properties of the PBC-40: a Dutch validation study | Rozanne de Veer | ![]() |
![]() |
|||
PO-1429 | Clinical and prognostic differences between non-alcoholic fatty liver disease and mixed fatty liver disease | Nicolau Vallejo-Senra | ![]() |
![]() |
|||
PO-1431 | Value assessment of sofosbuvir-based regimens for (chronic) hepatitis C in Spain | Raquel Domínguez-Hernández | ![]() |
![]() |
|||
PO-1436 | Ultra- processed food is associated with features of the metabolic syndrome and NAFLD | Dana Ivancovsky Wajcman | ![]() |
![]() |
|||
PO-1441 | Characterization and study of hepatic stellate cells in a 3D bioengineered model of fibrosis | Sara Campinoti | ![]() |
![]() |
|||
PO-1448 | Excellent virological and clinical responses maintained over 3 years of continuous Bulevirtide treatment in patients with HDV compensated cirrhosis and clinically significant portal hypertension | Alessandro Loglio | ![]() |
![]() |
|||
PO-1449 | Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients | Beatriz Mateos Muñoz | ![]() |
![]() |
|||
PO-1450 | Secreted hepatitis B virus (HBV) RNA associates to extracellular vesicles in supernatant of infected hepatocytes | Delphine Bousquet | ![]() |
![]() |
|||
PO-1451 | Characterization of circulating hepatitis B virus (HBV) RNA in chronic hepatitis B (CHB) patients | doohyun kim | ![]() |
![]() |
|||
PO-1453 | Screening for non-alcoholic fatty liver disease (NAFLD)-related advanced fibrosis, real life data and comparison of two endocrinology-hepatology referral strategies | Cyrielle Caussy | ![]() |
![]() |
|||
PO-1459 | Recipient age influences the short- and long-term survival after liver transplant: results of the French national cohort 2007-2017 | marianne Latournerie | ![]() |
![]() |
|||
PO-1460 | Harnessing liver-resident gamma delta T cells for immunotherapy of hepatocellular carcinoma | Nekisa Zakeri | ![]() |
![]() |
|||
PO-1462 | Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis | Francis Teh | ![]() |
![]() |
|||
PO-1471 | Myostatin is associated with sarcopenia and in combination with creatinine phosphokinase or albumin may be used as a screening tool of sarcopenia in liver cirrhosis | Theodoros Alexopoulos | ![]() |
![]() |
|||
PO-1472 | CD4 T cell tolerance induced by nanoparticle-mediated autoantigen delivery to liver sinusoidal endothelial cells depends on interferon-gamma | Daria Krzikalla | ![]() |
![]() |
|||
PO-1474 | A new strategy to screen varices needing treatment via risk ranked from 0 to 100 by VARS and VANT tests | Paul Calès | ![]() |
![]() |
|||
PO-1480 | Epidemiological evaluation of the liver cirrhosis in Albania: comparison with the historical data and indications to antiviral treatment appropriateness | Xhimi Tata | ![]() |
![]() |
|||
PO-1484 | Prevalence of immunological tolerance among type 1 autoimmune hepatitis patients on long-term remission | Maria Carlota Londoño | ![]() |
![]() |
|||
PO-1486 | Patient perspective on treatment and prognosis in Primary Biliary Cholangitis: a descriptive study | Maria van Hooff | ![]() |
![]() |
|||
PO-1496 | Impact of bacterial infections prior liver transplantation on post-transplant outcomes in patients with cirrhosis | Simone Incicco | ![]() |
![]() |
|||
PO-1500 | Dose adjustment of chelators based on urinary copper excretion after a drug free holiday - the first step to personalized medicine in patients with Wilson disease | Karin Kozbial | ![]() |
![]() |
|||
PO-1501 | Ascitic fluid lactic acid is an accurate predictor of mortality in patients with spontaneous bacterial peritonitis | Theodoros Alexopoulos | ![]() |
![]() |
|||
PO-1504 | An independent blinded review of suspected drug-induced liver injury (DILI) in nonalcoholic steatohepatitis (NASH) patients by a panel of pathologists and hepatologists: lessons learned from the seladelpar hepatoxicity review committee (SHRC) | Paul Watkins | ![]() |
![]() |
|||
PO-1505 | Fibrosis Biomarkers CA15-3 and Thrombospondin-2 are Associated with Higher Hepatic Collagen Content in Non-alcoholic Steatohepatitis (NASH)-related Fibrosis | Carey Escheik | ![]() |
![]() |
|||
PO-1508 | Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs | Ryan Buchanan | ![]() |
![]() |
|||
PO-1510 | Serum markers of HBV cccDNA transcriptional activity - HBcrAg and pre-genomic HBV RNA, pre-treatment HDV RNA and HDV genotype are useful markers in predicting treatment responses to pegylated interferon in HDV infection | Ivana Carey | ![]() |
![]() |
|||
PO-1512 | Multimarker analysis combining markers of fibrosis and inflammation in primary sclerosing cholangitis | Guri Fossdal | ![]() |
![]() |
|||
PO-1518 | Serum metabolomics-based steatohepatitis score for the non-invasive identification of patients with non-alcoholic steatohepatitis (NASH) in multiethnic, including type 2 diabetes mellitus population | Pablo Ortiz | ![]() |
![]() |
|||
PO-1519 | Endoscopic surveillance of esophageal varices could be refined in HBV compensated cirrhotics taking Tenofovir or Entecavir: an 11-year real-life study | Elisa Farina | ![]() |
![]() |
|||
PO-1522 | Voices of italian patients with Wilsons disease: results from a quality survey | Viviana Anelli | ![]() |
![]() |
|||
PO-1523 | Significantly higher mortality post liver transplantation in patients with psychosocial risk factors | Jeevan Barn | ![]() |
![]() |
|||
PO-1525 | Nurse intervention optimizes the care of patients with hepatocellular carcinoma under systemic treatment | Gemma Iserte | ![]() |
![]() |
|||
PO-1526 | The natural history of pediatric Non-alcoholic Fatty Liver Disease: a long term follow up study | Laura Draijer | ![]() |
![]() |
|||
PO-1533 | FULL DOSE SOFOSBUVIR - VELPATASVIR IN CHRONIC HEPATITIS C IN PATIENTS WITH END STAGE RENAL DISEASE. | AADIL ASHRAF | ![]() |
![]() |
|||
PO-1541 | Potential underlying mechanisms in the immune response to COVID in obese heavy drinkers | Martí Ortega Ribera | ![]() |
![]() |
|||
PO-1542 | Metabolic comorbidities reduce the improvement of procoagulant imbalance in non-cirrhotic patients with chronic hepatitis C (CHC) after viral eradication with direct-acting antiviral agents (DAAs) | Giordano Sigon | ![]() |
![]() |
|||
PO-1547 | Steatosis, inflammasome upregulation and fibrosis are attenuated in microRNA-155 deficient mice in a diet-induced model of NASH | Mrigya Babuta | ![]() |
![]() |
|||
PO-1549 | Circulating microRNAs profiling in acute decompensation of liver cirrhosis | Yasmina Chouik | ![]() |
![]() |
|||
PO-1551 | The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry | Carey Escheik | ![]() |
![]() |
|||
PO-1553 | Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-December 2020 | Tengiz Tsertsvadze | ![]() |
![]() |
|||
PO-1558 | Hepatobiliary Changes in Intestinal Disorders | Jessica Voss | ![]() |
![]() |
|||
PO-1561 | Risk of hepatocellular carcinoma after HCV eradication: capturing the role of portal hypertension | Elton Dajti | ![]() |
![]() |
|||
PO-1563 | Longer-term Outcome from Alcoholic Hepatitis: survival, re-admission rate and out-patient attendance after discharge | Ewan Forrest | ![]() |
![]() |
|||
PO-1568 | Longitudinal variability of noninvasive tests of fibrosis: Implications for treatment response monitoring in patients with NASH | Andrew Billin | ![]() |
![]() |
|||
PO-1572 | Screening and treatment of Hepatitis C virus in Hungarian prisons: 13 years of experience | Magyar Alapítvány | ![]() |
![]() |
|||
PO-1574 | MARC1 p.A165T polymorphism is associated with decreased liver injury and enhanced antioxidant activity in serum in patients with AIH | Maciej Janik | ![]() |
![]() |
|||
PO-1575 | Fibrosis response assessed by enhanced liver fibrosis and FibroScan liver stiffness measurement in patients with non-alcoholic steatohepatitis treated with subcutaneous semaglutide | Quentin Anstee | ![]() |
![]() |
|||
PO-1578 | Should normal liver blood tests be the treatment target in primary biliary cholangitis? | Aaron Wetten | ![]() |
![]() |
|||
PO-1579 | Chinese traditional medicine Yiqi Huoxue recipe attenuates hepatic fibrosis via the YAP/TAZ signaling | Wen Zhao | ![]() |
![]() |
|||
PO-1580 | Prospective screening of significant liver fibrosis in a large cohort of 131,861 French subjects using, since October 2020, automatic calculation of FIB-4 in routine blood tests. | DENIS OUZAN | ![]() |
![]() |
|||
PO-1588 | Comorbidity and healthcare utilization burden of patients diagnosed with non-alcoholic steatohepatitis based on fibrosis-4 score severity | Christine Coco | ![]() |
![]() |
|||
PO-1589 | Non-alcoholic steatohepatitis-related costs changes in the context of fibrosis progression status in European patients | Leonardo Ruiz Casas | ![]() |
![]() |
|||
PO-1593 | The Caserta Model: a way for HCV free Hospitals, a simplified procedure for HCV micro-elimination | vincenzo messina | ![]() |
![]() |
|||
PO-1598 | Investigating the potential association of elevated plasma Leukotriene B4 and survival in females in the ATTIRE trial | Thais Helena Tittanegro | ![]() |
![]() |
|||
PO-1605 | Detection of novel biomarkers in HBV-associated chronic hepatitis, liver fibrosis/cirrhosis, and hepatocellular carcinoma utilizing transcriptome sequencing technology | Dandan Zhao | ![]() |
![]() |
|||
PO-1606 | FXR agonists increase liver-derived serum alkaline phosphatase (ALP) by species-specific pharmacologic mechanisms independent of cholestasis | Justin Schumacher | ![]() |
![]() |
|||
PO-1609 | The impact of liver fibrosis progression on the Health-related quality of life of patients with non-alcoholic steatohepatitis in clinical practice in Europe | Leonardo Ruiz Casas | ![]() |
![]() |
|||
PO-1613 | Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease | Katharina Pomej | ![]() |
![]() |
|||
PO-1615 | Role of cytosolic phospholipase A2 and 5-lipoxygenase for ammonia-induced astrocyte senescence | Philipp Heimers | ![]() |
![]() |
|||
PO-1622 | Efficacy of hepatitis B virus vaccines HBVaxpro40 and Fendrix in patients with chronic liver disease in clinical practice | Diana Horta | ![]() |
![]() |
|||
PO-1623 | Treatment of alcohol withdrawal syndrome in patients with alcohol-related liver disease | Alexander Doyle | ![]() |
![]() |
|||
PO-1624 | Planning the Hepatitis C elimination in Cyprus: A modeling study | Ilias Gountas | ![]() |
![]() |
|||
PO-1626 | Rilpivirine-induced anti-inflammatory effects in non-alcoholic fatty liver disease involve the inhibition of CCL2/CCR2 axis | Ángela B. Moragrega | ![]() |
![]() |
|||
PO-1628 | Comparison of hepatitis B virus relapses between hepatitis B e antigen-negative chronic hepatitis B patients who discontinue tenofovir disoproxil fumarate with or without switching to alafenamide | Chien--Hung Chen | ![]() |
![]() |
|||
PO-1629 | Influence on cancer cell energy metobolism by pharmocological inhibition of the histone modifying lysine-specific demethylase 1 | Jie Wang | ![]() |
![]() |
|||
PO-1631 | A cell culture model of primary human hepatocytes derived from HBV-infected humanized mice for antiviral drug evaluation | Jan-Hendrik Bockmann | ![]() |
![]() |
|||
PO-1641 | Long-term treatment with odevixibat improves multiple sleep parameters in patients with progressive familial intrahepatic cholestasis: a pooled responder analysis from the phase 3 PEDFIC studies | Julie Collins | ![]() |
![]() |
|||
PO-1643 | Nutritional supplementation with B-Hydroxy-B-methylbutyrate (HMB) in malnourished cirrhotic patients | Silvia Espina | ![]() |
![]() |
|||
PO-1644 | A deep learning approach to analysis of MRCP images predicts clinical events and progression to cirrhosis in patients with primary sclerosing cholangitis | AADITYA PRAKASH | ![]() |
![]() |
|||
PO-1648 | Clinical utility of 30 relative decline in MRI-PDFF in predicting fibrosis regression in nonalcoholic fatty liver disease | Nobuharu Tamaki | ![]() |
![]() |
|||
PO-1649 | Acute liver injury results in temporal changes in hepatic macrophage pool | Anna Bujko | ![]() |
![]() |
|||
PO-1651 | Histological lesions can predict response to corticosteroids in patients with severe alcohol-related steatohepatitis | Carolin Lackner | ![]() |
![]() |
|||
PO-1653 | Sustained delivery of IL-10 using an innovative cell-based platform for immune-mediated hepatitis | Sofia Brites Boss | ![]() |
![]() |
|||
PO-1654 | Changes in alcohol-related liver disease admissions over the time of minimum unit pricing of alcohol: the GRI Q4 study | Sardar Chaudhary | ![]() |
![]() |
|||
PO-1661 | Outcomes and characteristics of hepatocellular carcinomas (HCC) in Caucasian chronic hepatitis B (CHB) patients treated with long-term entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy | George Papatheodoridis | ![]() |
![]() |
|||
PO-1664 | Incidence of hepatic outcomes in patients with cirrhosis due to primary biliary cholangitis: A population-based epidemiology study | Christine Coco | ![]() |
![]() |
|||
PO-1665 | Substantial clinical benefits with odevixibat treatment across progressive familial intrahepatic cholestasis genetic deficiencies: subgroup analysis of serum bile acids, pruritus, and safety using pooled data from the PEDFIC 1 and 2 studies | Julie Collins | ![]() |
![]() |
|||
PO-1666 | Telemedicine improve HCV elimination among Italian people who use drugs: an innovative therapeutic model to increase the adherence to treatment into addiction care centers. | Valerio Rosato | ![]() |
![]() |
|||
PO-1667 | Elevated serum bile acids in NASH patients with fibrosis in the context of their cholestatic genetic predisposition | Monika Rau | ![]() |
![]() |
|||
PO-1668 | Extracorporeal non-invasive assessment of the hepatobiliary function using novel bile acid derivatives with near-infrared fluorescence | Jose Marin | ![]() |
![]() |
|||
PO-1670 | Use of rifaximin is not associated with infections by multi-drug resistant bacteria, but with occurrence of rifampicin-resistance in coagulase-negative staphylococci | Lina Marise Schulte | ![]() |
![]() |
|||
PO-1684 | Low-grade hyperammonemia induces severe neuronal mitochondrial dysfunction in cellular and animal models of hepatic encephalopathy | Annarein Kerbert | ![]() |
![]() |
|||
PO-1688 | Insights on the antiviral mechanisms of action of a TLR1/2 agonist in hepatitis B virus infected hepatocytes | Manon Desmares | ![]() |
![]() |
|||
PO-1689 | Combination treatment with cilofexor and firsocostat leads to improvements in the FibroScan-AST (FAST) score in patients with advanced fibrosis due to NASH | Rohit Loomba | ![]() |
![]() |
|||
PO-1691 | Feasibility and effectiveness of models of hepatitis C viremia testing at harm reduction sites in Georgia: a prospective 3 arm study | Maia Japaridze | ![]() |
![]() |
|||
PO-1693 | Frailty in non-alcoholic fatty liver cirrhosis in comparison to alcoholic cirrhosis, risk patterns and impact on prognosis | Tomas Koller | ![]() |
![]() |
|||
PO-1696 | Diagnostic Accuracy of Transient Elastography in Diagnosing Clinically Significant Portal Hypertension in Patients with Chronic Liver Disease: A Systematic Review and Meta-analysis | Ashish Kumar | ![]() |
![]() |
|||
PO-1699 | Discovery and preclinical profile of VNRX-9945, a potent, broadly active core protein inhibitor for the treatment of hepatitis B virus (HBV) infection | Glen Coburn | ![]() |
![]() |
|||
PO-1701 | Low incidence of SARS-CoV-2 infection in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a German tertiary center during the 2020 pandemic | Lilith Kuballa | ![]() |
![]() |
|||
PO-1705 | Application of a machine learning model to improve performance of endoscopic classification for prediction bleeding in patients with compensated cirrhosis with esophageal varices | Samagra Agarwal | ![]() |
![]() |
|||
PO-1707 | Cloning and in vivo characterization of a new hepatitis D virus genotype 1 strain from a patient achieving sustained virus response to interferon alpha treatment | Katja Giersch | ![]() |
![]() |
|||
PO-1708 | Hallmarks of neutrophil extracellular trap (NET) components in the course of alcoholic liver disease | Anna Rycyk | ![]() |
![]() |
|||
PO-1711 | Inducers of the NF-kB pathways impair Hepatitis Delta virus (HDV) replication & strongly decrease progeny infectivity and spreading | Julie Lucifora | ![]() |
![]() |
|||
PO-1712 | Baseline liver volume is a major prognostic factor in acute decompensation of alcohol-associated cirrhosis: results from the prospective multicentre PROLIV study | José Ursic-Bedoya | ![]() |
![]() |
|||
PO-1713 | Changes in Liver Transplant Wait-List Trends in Young American Adults: 2003-2018 | George Philip | ![]() |
![]() |
|||
PO-1714 | Liver stiffness by vibration-controlled transient elastography predicts disease progression in patients with advanced fibrosis due to NASH | Rohit Loomba | ![]() |
![]() |
|||
PO-1718 | Genetic analysis and phenotypic correlation in ductal plate malformation | Meha Bhuva | ![]() |
![]() |
|||
PO-1722 | Epidemiology and burden of Progressive Familial Intrahepatic Cholestasis: Systematic review | Velichka Valcheva | ![]() |
![]() |
|||
PO-1725 | Health-related quality of life and stigma related to chronic hepatitis B: a systematic literature review | Vera Gielen | ![]() |
![]() |
|||
PO-1727 | Combination therapy of lanifibranor and firsocostat further improves steatohepatitis and fibrosis compared to monotherapy in a diet-induced murine model of NASH | Guillaume Wettstein | ![]() |
![]() |
|||
PO-1729 | Risk based HCC surveillance has the potential to minimise patient harm | Chris Curran | ![]() |
![]() |
|||
PO-1730 | Cirrhotic patients without prior antibiotic exposure may be eligible to lower first-line antibiotic strategies for nosocomial infections: results from a local antibiotic resistance study | Fanny Lebossé | ![]() |
![]() |
|||
PO-1745 | Equal overall survival in elderly patients with hepatocellular carcinoma receiving palliative treatment | Thorben Frndt | ![]() |
![]() |
|||
PO-1747 | Spleen size does not correlate with histological stage of liver disease in people with non-alcoholic fatty liver disease | Tessa Cacciottolo | ![]() |
![]() |
|||
PO-1748 | Improvement in itch correlates with improved sleep in GLIMMER, a Phase 2b trial of linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis | David Jones | ![]() |
![]() |
|||
PO-1752 | Human antigen R (HuR) SUMOylation fine-tunes hepatocellular carcinoma (HCC) progression by modulating the expression of mitochondrial mRNAs | Sofia Lachiondo-Ortega | ![]() |
![]() |
|||
PO-1753 | Implication of the Patatin-like phospholipase domain-containing 3 I148M mutation on hepatic stellate cells mitochondrial dysfunction and profibrogenic potential | Elisabetta Caon | ![]() |
![]() |
|||
PO-1755 | Younger age is associated with lower self-reported quality of life among patients with autoimmune disease during Canadas response to the COVID-19 pandemic | Christina Plagiannakos | ![]() |
![]() |
|||
PO-1758 | Circulating Fn14 is associated with pathogenic TH17 polarization in children with sclerosing cholangitis and inflammatory bowel disease | Simon Lam | ![]() |
![]() |
|||
PO-1761 | SLEEP STUDY WITH ACTIGRAPHY IN PATIENTS AFFECTED BY CIRRHOSIS WITH AND WITHOUT MINIMAL HEPATIC ENCEPHALOPATHY | Carmina Montoliu | ![]() |
![]() |
|||
PO-1762 | Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, metabolism, and in histologic parameters following treatment with efruxifermin | Erik Tillman | ![]() |
![]() |
|||
PO-1763 | Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathyShort title: RIFSYS Trial | Debbie Shawcross | ![]() |
![]() |
|||
PO-1766 | High risk medication-related problems are associated with lower quality of life in decompensated cirrhosis | Kelly Hayward | ![]() |
![]() |
|||
PO-1767 | The prevalence of sarcopenia and myosteatosis in cirrhotic patients: preliminary results from an italian multicenter study (EpatoSarco Group) | Simone Di Cola | ![]() |
![]() |
|||
PO-1771 | The expressions of CCNB1, CDC20 and CENPF is both peripheral blood and liver is associated with anti-tumour immunity in HCC | Zhenlin Huang | ![]() |
![]() |
|||
PO-1773 | Clinical value of surveillance biopsies in pediatric liver transplantation: A single center experience with 800 biopsies | Brittany Rocque | ![]() |
![]() |
|||
PO-1775 | GST-HG141, a novel clinical-stage hepatitis B virus capsid assembly modulator | Vadim Bichko | ![]() |
![]() |
|||
PO-1777 | The Metabolomics of Non-Alcoholic Fatty Liver Disease: Of Networks and Biomarkers | Aidan McGlinchey | ![]() |
![]() |
|||
PO-1781 | HCC incidence is low after HBsAg seroclearance in off-Nuc patients | Rachel Wen-Juei Jeng | ![]() |
![]() |
|||
PO-1787 | Markers of neutrophil extracellular traps are elevated in patients with Child-Pugh B and C liver cirrhosis | Robin Zenlander | ![]() |
![]() |
|||
PO-1788 | The incidence and predictors of HCC in REVEAL chronic hepatitis B patients with incident spontaneous HBsAg loss | Rachel Wen-Juei Jeng | ![]() |
![]() |
|||
PO-1789 | Characterization of the Liver Immune Microenvironment in Chronic HBV Infected Patient Liver Biopsies | Nicholas Van Buuren | ![]() |
![]() |
|||
PO-1790 | National audit of diagnosis, management and surveillance in primary sclerosis cholangitis (PSC) in the United Kingdom. | Evangelia Fatourou | ![]() |
![]() |
|||
PO-1791 | Hepatic decompensation and hepatocellular carcinoma after stopping nucleos(t)ide analogue therapy: Results from a large, global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study) | Grishma Hirode | ![]() |
![]() |
|||
PO-1797 | Effect of seladelpar and CB-0406 combination therapy on obesity, liver fibrosis and steatosis in a diet-induced obese (DIO) mouse model of biopsy-confirmed non-alcoholic steatohepatitis (NASH) with fibrosis | Charles McWherter | ![]() |
![]() |
|||
PO-1799 | Among cancer patients, autoimmune hepatitis with cirrhosis increases mortality | Morten Daniel Jensen | ![]() |
![]() |
|||
PO-1801 | Evolutionary learning derived clinical-radiomic models for predicting early recurrence of hepatocellular carcinoma after surgical resection | I-Cheng Lee | ![]() |
![]() |
|||
PO-1809 | Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies | Stuart C Gordon | ![]() |
![]() |
|||
PO-1811 | Odevixibat effects on cholestasis-related parameters: Analysis of pooled data from the PEDFIC 1 and PEDFIC 2 studies in children with progressive familial intrahepatic cholestasis | Julie Collins | ![]() |
![]() |
|||
PO-1813 | General population testing for hepatitis B in Australia: a cost-effectiveness analysis | Yinzong Xiao | ![]() |
![]() |
|||
PO-1817 | Decreased hepatitis B and C testing in Ontario, Canada during the first wave of the COVID-19 pandemic | Erin Mandel | ![]() |
![]() |
|||
PO-1819 | KS-356, a novel inhibitor of TGF-beta superfamily signaling, improves obesity and obesity-related hepatic steatosis by inhibition of TGF-beta/Smad3 signaling pathway in high-fat diet-induced mice | Kisoo Pahk | ![]() |
![]() |
|||
PO-1822 | Cellular immune responses to human betaretrovirus in patients with primary biliary cholangitis | Hiatem Abofayed | ![]() |
![]() |
|||
PO-1823 | Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease: a nationwide cohort study | Min Na Kimi | ![]() |
![]() |
|||
PO-1825 | Programmed Death-Ligand 1 protein is preferentially expressed in tumor-associated macrophages in peritumoral regions of hepatocellular carcinoma | Pil Soo Sung | ![]() |
![]() |
|||
PO-1826 | Agreement in non-invasive fibrosis risk assessments in a primary care NAFLD cohort | Andrew Schreiner | ![]() |
![]() |
|||
PO-1828 | Genetic mutation and cystic fibrosis-associated liver disease at the time of diagnosis in children: A correlational study | ALEJANDRA SABILLON | ![]() |
![]() |
|||
PO-1831 | Combinations of an acetyl CoA carboxylase inhibitor, FXR agonist and GLP-1R agonist inhibits fibrosis progression in the rat choline-deficient, L-amino acid defined, high-fat diet model of advanced fibrosis | ARCHANA VIJAYAKUMAR | ![]() |
![]() |
|||
PO-1833 | Odevixibat therapy improves clinically meaningful endpoints in children with progressive familial intrahepatic cholestasis: Data from the PEDFIC 1 and PEDFIC 2 trials | Julie Collins | ![]() |
![]() |
|||
PO-1837 | HBsAg, anti-HBs and ALT kinetic characterization during NAP-based combination therapy of HBeAg negative chronic hepatitis B infection | Harel Dahari | ![]() |
![]() |
|||
PO-1839 | The Association of Dietary Factors and Physical Activity with Sarcopenia in Non-Alcoholic Fatty Liver Disease (NAFLD) | Carey Escheik | ![]() |
![]() |
|||
PO-1841 | Earlier and more frequent virological and clinical relapse after cessation of tenofovir disoproxil fumarate versus entecavir therapy: Results from a global, multi-ethnic cohort of chronic hepatitis B patients (RETRACT-B study) | Hannah Choi | ![]() |
![]() |
|||
PO-1843 | Pretreatment serum bile acid parameters and predictability of response to odevixibat, an ileal bile acid transport inhibitor, in children with progressive familial intrahepatic cholestasis | Julie Collins | ![]() |
![]() |
|||
PO-1849 | A3907, a novel orally available inhibitor of the apical sodium-dependent bile acid transporter, improves key clinical markers of non-alchoholic steatohepatitis in obese diet-induced and biopsy-confirmed mouse models | PETER AKERBLAD | ![]() |
![]() |
|||
PO-1851 | Significant lipid lowering by ASC41oral tablet,a liver targeted THR agonist,in a phase I randomized,double-blind,placebo controlled single- and multiple-ascending dose study | Mingfei Ge | ![]() |
![]() |
|||
PO-1856 | Anti-tumor activity of TRN-000546, a liver-distributed monophosphate prodrug of FdUMP, in orthotopic liver tumor models | Kevin Klucher | ![]() |
![]() |
|||
PO-1857 | AI digital pathology using qFibrosis reveals heterogeneity of fibrosis regression in hepatitis B and C patients with SVR | Feng Liu | ![]() |
![]() |
|||
PO-1862 | Predictors of loss to follow-up in an outpatient cirrhotic population | Joana Vieira Barbosa | ![]() |
![]() |
|||
PO-1865 | Association between non-alcoholic fatty liver disease and extrahepatic malignancy | Mesut GM&350;SOY | ![]() |
![]() |
|||
PO-1871 | Screening, enhancement of access to care and prioritization of treatment of chronic hepatitis C infection in high-risk population in Hong Kong | Lung-Yi Loey Mak | ![]() |
![]() |
|||
PO-1872 | A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison | Anna Palmer | ![]() |
![]() |
|||
PO-1876 | Novel shapelet patterns for time series classification (TSC) for AFP and ALT to predict HCC in patients with chronic hepatitis B on antiviral treatment | Vicki Hui | ![]() |
![]() |
|||
PO-1877 | Feasibility, effectiveness, and lessons learned from the introduction of decentralised HCV testing and treatment at primary healthcare clinics in three regions in Malaysia | Xiao Hui Sem | ![]() |
![]() |
|||
PO-1880 | Association between Non-alcoholic Fatty Liver Disease and the Risk of Dementia: A Nationwide Cohort Study | Gi-Ae Kim | ![]() |
![]() |
|||
PO-1885 | ALKBH5-modified HMGB1-STING activation contributes to radiation-induced liver disease via innate immune response | Genwen Chen | ![]() |
![]() |
|||
PO-1895 | Evaluation of the Fibrosis-4 score for referral from primary care patients for NAFLD in Belgium | Leen Heyens | ![]() |
![]() |
|||
PO-1897 | Men and women display different predictive biomarkers of NASH: a machine learning approach | Gerard Baiges Gaya | ![]() |
![]() |
|||
PO-1899 | A novel liver-specific fibrosis biomarker, PRO-C18L, can predict response to antifibrotic treatment, with a peroxisome proliferator activated receptor -y agonist, in patients with chronic hepatitis C | Ida Villesen | ![]() |
![]() |
|||
PO-1904 | Low skeletal muscle mass is a potential risk factor for lean non-alcoholic fatty liver disease in patients with non-alcoholic fatty liver disease | Min Kyu Kang | ![]() |
![]() |
|||
PO-1907 | Viral interference in a hepatitis C virus and hepatitis E virus co-infection system | Thomas Burkard | ![]() |
![]() |
|||
PO-1908 | Significant Improvement of NAFLD Activity Scores and Liver Fibrosis by ASC41, a Selective THR- Agonist, in HIgh Fat Diet Induced NASH SD Rats | weifeng shi | ![]() |
![]() |
|||
PO-1916 | Co-stimulatory signals mediated by ICOS/ICOS-L dyad influence the differentiation of liver NASH-associated macrophages (NAMs) | Laila Lavanya Gadipudi | ![]() |
![]() |
|||
PO-1917 | Significant in-Vitro and in-Vivo inhibition of HBsAg and HBV pgRNA with ASC42,a novel non-steroidal FXR agonist | flutter ger | ![]() |
![]() |
|||
PO-1918 | The impact of hepatitis C virus eradication on hepatocarcinogenesis in haemophiliacs | Yosuke Inukai | ![]() |
![]() |
|||
PO-1919 | Long term follow-up in HCV infected patients with end stage chronic kidney disease after DAA therapy | Joan Martínez-Campreciós | ![]() |
![]() |
|||
PO-1927 | In vivo SPECT imaging of steatohepatitis in NAFLD preclinical models using VCAM-1 nanobody: a proof-of-concept study | Maxime Nachit | ![]() |
![]() |
|||
PO-1928 | Unexpected rising in the circulation of HBV complex profiles with HBsAg vaccine-escape mutations in HBV genotype-D: potential implications for HBsAg detection/quantification and vaccination strategies | Lorenzo Piermatteo | ![]() |
![]() |
|||
PO-1929 | Discovery of conserved HDV-specific CD8 T-cell epitopes in HDV/HBV co-infection | Valerie Oberhardt | ![]() |
![]() |
|||
PO-1930 | Albumin dysfunction correlates with disease markers in patients with decompensared cirrhosis | Raquel Horrillo | ![]() |
![]() |
|||
PO-1932 | Results of a screening program of liver fibrosis with transient elastography in subjects with alcohol use disorder | EMMA AVITABILE | ![]() |
![]() |
|||
PO-1935 | The hepatoprotective role of the antiretroviral drug Rilpivirine is associated with altered autophagy in in vitro and in vivo models of liver fibrosis | Federico Lucantoni | ![]() |
![]() |
|||
PO-1936 | A global systematic review of efforts to accelerate the elimination of hepatitis C virus (HCV) through micro-elimination | Jeffrey V Lazarus | ![]() |
![]() |
|||
PO-1942 | Blockade of IL-1 signaling in hepatocytes reduces tumor growth in a mouse model of NAFLD-related HCC | Nadine Gehrke | ![]() |
![]() |
|||
PO-1947 | Etiology and clinical characteristics of acute hepatitis in South Korea: A prospective, multicenter Study | Gwang Hyeon Choi | ![]() |
![]() |
|||
PO-1949 | Role of hypoxia-inducible factors 1alpha and 2alpha in prognosis and sorafenib chemoresistance in hepatocarcinoma | Carolina Méndez-Blanco | ![]() |
![]() |
|||
PO-1950 | An antibody microarray identifies epidermal growth factor receptor as a novel host factor of hepatitis E virus | Jil Alexandra Schrader | ![]() |
![]() |
|||
PO-1951 | Metabolic dysfunction Associated Fatty Liver Disease improves detection of high liver stiffness: The Rotterdam Study | Laurens Van Kleef | ![]() |
![]() |
|||
PO-1957 | Resistance to sorafenib in hepatocarcinoma: role of BCL2 interacting protein 3 promoter hypermethylation | Paula Fernández-Palanca | ![]() |
![]() |
|||
PO-1961 | Significant improvement of NAFLD activity scores and liver fibrosis by ASC42,a novel non-steroidal FXR agonist,in high fat diet induced NASH mice | Mingfei Ge | ![]() |
![]() |
|||
PO-1962 | Validation of a simple score to identify patients who can safely use protease inhibitor-based therapy for HCV infection | Lisette Krassenburg | ![]() |
![]() |
|||
PO-1966 | Hepatitis C elimination in the Netherlands (CELINE): nationwide retrieval of lost to follow-up chronic hepatitis C patients is feasible and worthwhile | Marleen van Dijk | ![]() |
![]() |
|||
PO-1969 | Abnormal glycosphingolipid patterns in human cholangiocarcinoma stem-like subset | Mirella Pastore | ![]() |
![]() |
|||
PO-1971 | Factors associated with unplanned intensive care unit readmission following liver transplantation | Marcus Robertson | ![]() |
![]() |
|||
PO-1980 | Quantified integrated hepatitis B virus DNA is related to viral activity in chronic hepatitis B patients | Robin Erken | ![]() |
![]() |
|||
PO-1981 | Non-invasive LIVERFASt transition rate to liver fibrosis is similar to that estimated with liver biopsy in NAFLD patients | Mona Munteanu | ![]() |
![]() |
|||
PO-1982 | Association between plasma miRNA-200-3p and transcriptional activity of hepatic cccDNA in chronic hepatitis B. | Vladimir Loukachov | ![]() |
![]() |
|||
PO-1983 | HLA-B27-restricted CD8 T-cell response against hepatitis B virus: viral escape as central mechanism of T-cell failure | Elahe Salimi Alizei | ![]() |
![]() |
|||
PO-1986 | The rs599839 AG variant disentangles cardiovascular risk and hepatocellular carcinoma in NAFLD patients | Marica Meroni | ![]() |
![]() |
|||
PO-1987 | Carvedilol improves risk of decompensation and survival in compensated cirrhosis. A competing-risk meta-analysis of individual patient data | Candid Villanueva | ![]() |
![]() |
|||
PO-1990 | The unmet needs of living with non-alcoholic steatohepatitis (NASH) in Europe and Canada: results from a multi-country survey | Jeffrey V Lazarus | ![]() |
![]() |
|||
PO-1996 | HBV reactivation can be predicted by combined highly-sensitive HBV markers: implications for an optimized management of HBsAg-negative/anti-HBc-positive oncohematological patients | Mohammad Alkhatib | ![]() |
![]() |
|||
PO-1998 | A study evaluating outcomes of cirrhotic patients managed virtually in a specialist liver cirrhosis service due to the COVID crisis. | Alex Cole | ![]() |
![]() |
|||
PO-2001 | Covid - 19 in Liver Transplant Recipients: A National Cohort | Gkhan Kabaam | ![]() |
![]() |
|||
PO-2006 | Anti-inflammatory and anti-fibrotic effects of icosabutate as mono- or combination therapy with a GLP-1 receptor agonist, a FXR agonist or an ACC inhibitor in a dietary mouse model of progressive fibrosis | David Fraser | ![]() |
![]() |
|||
PO-2008 | Sequential non-invasive assessments improve predictability for liver-related events in direct antivirals-treated chronic hepatitis C patients | Yen-Chun Liu | ![]() |
![]() |
|||
PO-2010 | Ethanol induced alterations in intestinal microbiota correlate with decreased intestinal nuclear receptor (PXR) pathway related proteins | Sudrishti Chaudhary | ![]() |
![]() |
|||
PO-2014 | The emergency department, a new setting for HBV screening in populations with limited linkage to the health care system in a high-income country | Jordi Llaneras | ![]() |
![]() |
|||
PO-2015 | Immunological Background Pinpoints Patients at High Risk of Immune-related Hepatitis Recurrence during Check-points Inhibitors Rechallenge | Ana Barreira | ![]() |
![]() |
|||
PO-2020 | Good practice hepatitis C screening and linkage to care initiatives at the SLTC Summit 2020: three out of four diagnosed patients able to start direct-acting antiviral treatment | Joaquin Cabezas | ![]() |
![]() |
|||
PO-2021 | Deferred direct-acting antiviral treatment in kidney transplantation from HCV-viremic donors into HCV-negative recipients. | Giulia Pagano | ![]() |
![]() |
|||
PO-2030 | Screening of advanced liver fibrosis in patients with coronary arterial disease, the CORONASH Study | thierry thevenot | ![]() |
![]() |
|||
PO-2032 | Disclosure of non-alcoholic steatohepatitis (NASH) diagnosis and fear of discrimination: results from a multi-country survey | Jeffrey V Lazarus | ![]() |
![]() |
|||
PO-2033 | TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models | Miriam Longo | ![]() |
![]() |
|||
PO-2039 | Anticipated timing of hepatitis C virus elimination in the Netherlands and the impact of COVID-19 | Marleen van Dijk | ![]() |
![]() |
|||
PO-2040 | Single-centre experience with follow up of patients with acute porphyria | Barbora Nováková | ![]() |
![]() |
|||
PO-2043 | The role of miR-873-5p in Alcohol-related Liver Disease | Rubén Rodríguez Agudo | ![]() |
![]() |
|||
PO-2047 | HCV screening of immigrants at arrival: an opportunity to linkage to care of a population with limited access to health care system | Mar Riveiro | ![]() |
![]() |
|||
PO-2048 | Rapid point of care HCV testing allows high throughput HCV screening and rapid treatment uptake among PWID attending a medically supervised injecting room | Michael MacIsaac | ![]() |
![]() |
|||
PO-2055 | The I148M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in Non-alcoholic Fatty Liver Disease (NAFLD) patients gains value | Erika Paolini | ![]() |
![]() |
|||
PO-2058 | Mesenchymal Stem Cell Transplantation in patients with cirrhosis and acute-on-chronic liver failure: A randomized, double-blind placebo control trial. | Enric Reverter | ![]() |
![]() |
|||
PO-2059 | Characterizing stigma related to non-alcoholic fatty liver disease (NAFLD) and obesity: a Twitter discourse analysis | Jeffrey V Lazarus | ![]() |
![]() |
|||
PO-2070 | Discriminatory changes in circulating lipid and small molecule metabolites in patients with MAFLD associated hepatocellular cancer | Rohini Sharma | ![]() |
![]() |
|||
PO-2074 | Systematic review with meta-analysis: Non-Alcoholic Fatty Liver Disease (NAFLD) in Pregnancy | Hydar El Jamaly | ![]() |
![]() |
|||
PO-2075 | Aspirin and the risk of hepatocellular carcinoma in chronic liver disease: A systematic review and meta-analysis | Jin Lin Tan | ![]() |
![]() |
|||
PO-2081 | Feasibility, effectiveness, and lessons learnt from decentralized HCV testing and treatment models among the general population in Delhi, India | Sonjelle Shilton | ![]() |
![]() |
|||
PO-2089 | HIF1a-mediated RelB/APOBEC3B downregulation allows Hepatitis B virus persistence | Tobias Riedl | ![]() |
![]() |
|||
PO-2090 | A 3-proteomic score to improve the clinical management of childhood liver cancer | Carolina Armengol | ![]() |
![]() |
|||
PO-2093 | Micro-elimination of hepatitis C achieved in HIV co-infected persons in Slovenia: analysis of HCV infection in a national HIV cohort | Jasna Cernosa | ![]() |
![]() |
|||
PO-2094 | Quantitate MR can identify paediatric patients with quiescent disease who may benefit from a change in treatment | Elizabeth Shumbayawonda | ![]() |
![]() |
|||
PO-2095 | Is elimination of hepatitis C across an entire prison network possible? A nurse-led test and treat model in 47 English prisons | Andy Jones | ![]() |
![]() |
|||
PO-2097 | Impact of COVID-19 pandemic on referral of patients with liver disease to a liver transplant center | Giacomo Germani | ![]() |
![]() |
|||
PO-2098 | GLAST redistributes, clusters and forms homomultimers at the membrane of astrocytes | Joana Patrícia Ventura Pereira | ![]() |
![]() |
|||
PO-2099 | Development of a disease-mimicking model for NASH and liver fibrosis in a triple cell-type, spheroid-based liver-on-chip platform with microfluidics | Geurt Stokman | ![]() |
![]() |
|||
PO-2103 | Changhua-Integrated Program to Stop Hepatitis C Infection (CHIPS-C) of Taiwan | Tsung-Hui Hu | ![]() |
![]() |
|||
PO-2105 | Hepatitis B virus surface antigen expression determines hepatic immunity and Kupffer cell functions in HBV-transgenic mice | Stefan Schefczyk | ![]() |
![]() |
|||
PO-2106 | T-cell engagers that bind HBV envelope proteins enable T cells to control the infection and to target hepatoma in mice | Oliver Quitt | ![]() |
![]() |
|||
PO-2108 | The global NAFLD preparedness index: are countries ready to tackle the challenge? | Jeffrey V Lazarus | ![]() |
![]() |
|||
PO-2113 | Proteomic profiling of hepatic stellate cell differentiation from induced pluripotent stem cells: new tools to understand liver development and fibrosis | Raquel A. Martinez Garcia de la Torre | ![]() |
![]() |
|||
PO-2120 | Treatment with seladelpar in patients with primary biliary cholangitis (PBC) and prior experience with obeticholic acid (OCA) or fibrates | Aliya Gulamhusein | ![]() |
![]() |
|||
PO-2121 | The impact of COVID-19 on liver transplant (LT) centers across the world during the first wave: a Multisociety Survey (EASL-ESOT/ELITA-ILTS) | Francesco Paolo Russo | ![]() |
![]() |
|||
PO-2122 | Decreased Overall Mortality and Mortality without Liver Transplantation with N-Acetylcysteine in Non-acetaminophen-induced Acute Liver Failure: A Systematic Review and Meta-Analysis | Adrian Alick Bonghanoy | ![]() |
![]() |
|||
PO-2123 | Liver Biopsy Graph Neural Networks for automated histologic scoring using the NASH CRN system | Maryam Pouryahya | ![]() |
![]() |
|||
PO-2127 | The road to hepatitis C virus elimination: entering the final stretch or chasing a moving finish line? | Sigurdur Olafsson | ![]() |
![]() |
|||
PO-2131 | A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi suggests an historic mechanism of transmission | Alexander Stockdale | ![]() |
![]() |
|||
PO-2134 | The association of serum hepatitis B core antibody and liver inflammation in HBeAg-negative chronic hepatitis B patients with normal ALT and detectable HBV DNA | Chao Wu | ![]() |
![]() |
|||
PO-2135 | A specific deletion pattern in the preS1- and preS2-domain is associated with treatment induced HBsAg loss in chronic hepatitis B | Maria Pfefferkorn | ![]() |
![]() |
|||
PO-2136 | Clinical decompensation and outcomes in patients with biopsy proven cirrhosis and a hepatic venous pressure gradient = 10 mm Hg | Ankur Jindal | ![]() |
![]() |
|||
PO-2138 | Safety and efficacy of direct acting antiviral therapy for chronic HCV infection in elderly people | Daniela Maggi | ![]() |
![]() |
|||
PO-2145 | Conservation, variability and evolution of Hepatitis Delta virus in antigen coding region | Beatriz Pacin | ![]() |
![]() |
|||
PO-2147 | Intestinal Epithelial Cell Death In Cirrhosis And Acute-on-Chronic Liver Failure | Stijn den Daas | ![]() |
![]() |
|||
PO-2152 | Modelling Clinical Outcomes of NASH in the United States Stratified by Presence of Type 2 Diabetes | Carey Escheik | ![]() |
![]() |
|||
PO-2154 | Characterization of in-vitro responses to different immune modulation of HBV core18-specific vs HBV pol455-specific CD8 T cells | Elmira Aliabadi | ![]() |
![]() |
|||
PO-2161 | Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice | Mohammad Kabbani | ![]() |
![]() |
|||
PO-2162 | Value of Hitachi Shear Wave Elastography (SWE) to rule-in and rule-out the presence of esophageal varices in patients with compensated advanced liver disease | Simona Bota | ![]() |
![]() |
|||
PO-2163 | Inhibition of integrin alphaVbeta1 and alphaVbeta6 by a small molecule inhibitor attenuated liver fibrosis and tumor formation in an advanced mouse NASH model | Dipankar Bhattacharya | ![]() |
![]() |
|||
PO-2173 | Treatment with GSK3228836 leads to HBsAg reduction and induction of interferon gamma related proteins and chemokines in a Phase 2a, randomized, double-blind, placebo-controlled study | Shihyun You | ![]() |
![]() |
|||
PO-2178 | Low baseline cortisol but not delta cortisol relates to 28-day transplant-free survival in acute liver failure syndromes | Sofia Roth | ![]() |
![]() |
|||
PO-2181 | Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma. A diagnostic test accuracy Cochrane review | Fraquelli Mirella | ![]() |
![]() |
|||
PO-2184 | Serum miRNA profiling for the differential diagnosis of distal cholangiocarcinoma from pancreatic diseases | André L. Simão | ![]() |
![]() |
|||
PO-2185 | Human Precision Cut Liver Slices as a model of Alcohol-related Liver Disease: recapitulating disease progression in a dish. | Elena Palma | ![]() |
![]() |
|||
PO-2186 | Imaging by Desorption electrospray ionization mass spectrometry detects changes in lobular patterns of lipids in non-alcoholic fatty liver disease | Patcharamon Seubnooch | ![]() |
![]() |
|||
PO-2191 | Directly observed therapy for hepatitis C alongside opioid agonist therapy as an effective microelimination strategy for PWIDs with a high risk for non-adherence in Vienna, Austria | Michael Schwarz | ![]() |
![]() |
|||
PO-2192 | Neddylation inhibition reduces liver steatosis in MAFLD mice models by promoting hepatic fatty acid oxidation via DEPTOR-mTOR axis | MARINA SERRANO-MACIÁ | ![]() |
![]() |
|||
PO-2193 | Evaluation of hepatitis C virus (HCV) core antigen assay from venepuncture compared to HCV RNA in plasma: a cohort study from Pakistan. | Saeed Hamid | ![]() |
![]() |
|||
PO-2194 | Multimodal assessment of neurocognitive impairment in a prospective cohort of patients with chronic liver disease:One third of patients do not have hepatic encephalopathy | Philippe Sultanik | ![]() |
![]() |
|||
PO-2203 | Diagnostic role of liver biopsy in patients with acute liver failure or acute liver injury | Peter Hunyady | ![]() |
![]() |
|||
PO-2204 | Modeling phenotypic heterogeneity of Glycogen Storage Disease type Ia liver disease in mice by somatic CRISPR/Cas9-mediated gene editing | Martijn Rutten | ![]() |
![]() |
|||
PO-2205 | Delivering elimination: rapid scale-up of hepatitis c virus treatment among people who inject drugs in Tayside, Scotland | Christopher Byrne | ![]() |
![]() |
|||
PO-2210 | A 3D in vitro screening-based discovery approach for ing and prioritizing NASH drug candidates | Radina Kostadinova | ![]() |
![]() |
|||
PO-2211 | Long-term survival after living donor liver transplantation in primary sclerosing cholangitis | Timur Liwinski | ![]() |
![]() |
|||
PO-2218 | Cost-effectiveness of a Core Antigen Based Rapid Diagnostic Test for Hepatitis C | Madeline Adee | ![]() |
![]() |
|||
PO-2223 | Proposal and validation of a novel scoring system for hepatocellular carcinomas beyond curability borders: Unresectable hepatocellular carcinoma prognostic index | Coskun Ozer Demirtas | ![]() |
![]() |
|||
PO-2227 | Diagnostic and prognostic value of miR-16, miR-146a and miR-192 in exosomes of hepatocellular and liver cirrhosis patients | Thorben Frndt | ![]() |
![]() |
|||
PO-2230 | Safety and efficacy of the JAK-inhibitor tofacitinib in patients with primary sclerosis cholangitis: a multicentre, retrospective study | Ida Schregel | ![]() |
![]() |
|||
PO-2234 | In vitro Transplantation of Biliary Organoids Support Hepatic Differentiation and proliferation in Chronic Liver Injury | Impreet Kaur | ![]() |
![]() |
|||
PO-2238 | Influence of Shunt occlusion on Organ Functions in Hyperammonemic patients with Cirrhosis having Porto-systemic Shunt: a randomized controlled trial | Amar Mukund | ![]() |
![]() |
|||
PO-2240 | Real-time utility of response-guided DAA therapy for hepatitis C based on a mathematical modeling approach:database formation and machine learning methods | Harel Dahari | ![]() |
![]() |
|||
PO-2242 | Incidence of Hepatocellular carcinoma in patients with Non-Alcoholic Fatty Liver Disease. A systematic Review, Meta-Analysis and Metaregression | Marco Sanduzzi Zamparelli | ![]() |
![]() |
|||
PO-2243 | Control of APOBEC3B induction and transcription-independent Hepatitis B virus episome decay by NF-kB and miR-138-5p | Suzanne Faure-Dupuy | ![]() |
![]() |
|||
PO-2259 | Intravenous ketamine and progressive cholangiopathy in covid-19 patients | Kilian Bock | ![]() |
![]() |
|||
PO-2261 | Changing demographic-clinic-pathologic profiles of newly diagnosed carriers of chronic hepatitis B virus infection across two decades: a single Italian reference center report | Gabriele Ricco | ![]() |
![]() |
|||
PO-2269 | HBsAg, HBcrAg, and HBV RNA in outcomes and after NA discontinuation in HBeAg negative patients with chronic hepatits B: results from the Toronto STOP Study | Arif Sarowar | ![]() |
![]() |
|||
PO-2273 | The impact of age in clinical outcomes in cirrhotic outpatients | Marta Tonon | ![]() |
![]() |
|||
PO-2275 | Prevalence of resistance associated substitutions in hepatitis C virus NS5A against direct acting antivirals | Zain Ul Abideen | ![]() |
![]() |
|||
PO-2276 | Ripk3 depletion improves mitochondrial bioenergetics and function in experimental NAFLD | Tawhidul Islam | ![]() |
![]() |
|||
PO-2279 | Obese-induced brain sphingolipid dysregulation in bile-duct ligated rats accelerates and exacerbates hepatic encephalopathy | Rafael Ochoa-Sanchez | ![]() |
![]() |
|||
PO-2280 | Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute on chronic liver failure | Sanchit Sharma | ![]() |
![]() |
|||
PO-2285 | Vitamin B6 deficiency associates with liver transplantation-free survival in primary sclerosing cholangitis | Peder Rusten Braadland | ![]() |
![]() |
|||
PO-2287 | Oral LPCN 1144 treatment significantly reduced liver fat and key liver injury markers in biopsy confirmed NASH subjects: Results of a Phase 2 randomized controlled study | Kilyoung Kim | ![]() |
![]() |
|||
PO-2290 | Aminotransferase improvements in patients with non-alcoholic steatohepatitis are associated with fibrosis regression in the REGENERATE study | Denise Frontin | ![]() |
![]() |
|||
PO-2293 | Low anti-HBc levels are associated with lower risk of virological relapse after discontinuation of nucleos(t)ide analogue therapy in HBe antigen negative patients. | Valerie Ohlendorf | ![]() |
![]() |
|||
PO-2294 | Prognostic impact of Hepatic venous pressure gradient cut-off of 10mm Hg to predict clinical decompensations in patients with compensated cirrhosis with liver stiffness above 25 kilopascals | Sanchit Sharma | ![]() |
![]() |
|||
PO-2295 | Amino acid substitutions associated with treatment failure of hepatitis C virus infection | Carlos García-Crespo | ![]() |
![]() |
|||
PO-2297 | BIO89-100 demonstrated robust reduction in liver fat fraction and liver fat volume (LFV) and favorable tolerability with weekly (QW) and every 2 weeks (Q2W) dosing in a Phase 1b/2a placebo-controlled proof of concept study in NASH | Maya Margalit | ![]() |
![]() |
|||
PO-2298 | Prediction of cardiac outcomes post-transjugular intrahepatic portosystemic shunt placement using cirrhotic cardiomyopathy criteria | Claire Harrington | ![]() |
![]() |
|||
PO-2305 | Rifaximin for Prophylaxis of Post-TIPPS Hepatic Encephalopathy- A Meta Analysis | Aminah Abdul Razzack | ![]() |
![]() |
|||
PO-2307 | Ex vivo immune checkpoint blockade differentially regulates IFN-gamma and IL-2 responses in HBV-specific T cells across clinical HBV phases | Conan Chua | ![]() |
![]() |
|||
PO-2312 | Novel liver-specific thyromimetic for the treatment of steatohepatitis | Andrea Perra | ![]() |
![]() |
|||
PO-2313 | IL-1Ra, IL-18 and TREM-1 circulating factors and CDve HLADR-low TIM3ve suppressive monocytes predict development of sepsis within 3 days in patients with acute on chronic failure | Pushpa Yadav | ![]() |
![]() |
|||
PO-2319 | Validation of non-invasive criteria for diagnosis of clinically significant portal hypertension in compensated advanced chronic liver disease of different etiologies in an asian cohort | Sanchit Sharma | ![]() |
![]() |
|||
PO-2320 | Efficacy and Safety of Sofosbuvir\Ledipasvir Combination or Nitazoxanide in Treatment of COVID-19: A Placebo-Controlled, Randomized Clinical Trial | Mohammed Medhat | ![]() |
![]() |
|||
PO-2322 | Exposure to environmental contaminants is associated with sex-specific disturbances of hepatic lipid metabolism in non-alcoholic fatty liver disease | Matej Oresic | ![]() |
![]() |
|||
PO-2324 | Incidence and impact of PYLEPHEBITIS in PYOGENIC LIVER ABSCESS | Nicolas Drilhon | ![]() |
![]() |
|||
PO-2326 | Assessment of how modifiable and non-modifiable factors can impact fibrosis outcomes in non-alcoholic steatohepatitis patients: a 12-country real-world assessment | Victoria Higgins | ![]() |
![]() |
|||
PO-2328 | NAFLD and colorectal adenoma - rather an association than causality | Georg Semmler | ![]() |
![]() |
|||
PO-2329 | High prevalence of low normal or overtly hypogonadal levels of testosterone observed in histologically established NASH subjects in LiFT Study | Benjamin Bruno | ![]() |
![]() |
|||
PO-2331 | Past hospital contacts due to alcohol do not predict fibrosis stage in alcohol-related liver disease. A study of alcohol diagnoses and morbidity in 18 years leading up to biopsy-proven liver fibrosis in 462 patients | Ditlev Nytoft Rasmussen | ![]() |
![]() |
|||
PO-2338 | Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy & safety results from a phase 2, open-label study | Young Suk Lim | ![]() |
![]() |
|||
PO-2339 | Impact of hepatitis B core-related antigen (HBcrAg) level on HBV specific CD4 and CD8 T cell responses in HBeAg negative patients with chronic hepatitis B virus infection | Elmira Aliabadi | ![]() |
![]() |
|||
PO-2341 | High oxidative stress in T cells and monocytes correlates with mortality from alcoholic hepatitis | Huey Tan | ![]() |
![]() |
|||
PO-2343 | Does fibrosis severity or diabetes status influence patient-reported lifestyle changes and degree of success among non-alcoholic steatohepatitis patients? | Victoria Higgins | ![]() |
![]() |
|||
PO-2352 | Beating Hepatitis C together in challenging times: an evaluation of a multi-disciplinary approach to testing and treating homeless people temporarily housed during the COVID-19 pandemic | Tracey Stirrup | ![]() |
![]() |
|||
PO-2358 | Pulmonary impairment determines mortality in critically ill patients with acute-on-chronic liver failure | Martin Schulz | ![]() |
![]() |
|||
PO-2359 | Hepatitis B and C screening in hospitalized SARS-CoV-2 patients | Judith Gómez-Camarero | ![]() |
![]() |
|||
PO-2363 | Role of farensoid-X receptor agonist in ameliorating NASH-disrupted intestinal permeability: Potential impact of autophagy on tight junctions | Rasha Tawfiq | ![]() |
![]() |
|||
PO-2364 | The added value of PIVKA-II levels over AFP in patients with hepatocellular carcinoma undergoing locoregional treatment | massimo iavarone | ![]() |
![]() |
|||
PO-2366 | Nonalcoholic fatty liver disease in chronic hepatitis B patients: patients characterization and impact on disease progression | Fadi Abu Baker | ![]() |
![]() |
|||
PO-2369 | Current non-invasive tests have suboptimal performance for the identification of candidates for pharmacological therapy for pre-cirrotic non-alcoholic steatohepatitis. | Jesús Rivera | ![]() |
![]() |
|||
PO-2370 | Evaluation of the newly proposed criteria for clinically significant portal hypertension using platelets and transient elastography | Kristian Podrug | ![]() |
![]() |
|||
PO-2375 | Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma | Campani Claudia | ![]() |
![]() |
|||
PO-2377 | Canagliflozin and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus (CaNAFLD) - A Secondary Analysis of Two Randomized Controlled Trials | Angel Borisov | ![]() |
![]() |
|||
PO-2381 | THE IMPROVEMENT IN BODY COMPOSITION INCLUDING ADIPOSE TISSUE REDUCES AMMONIA AND HEPATIC ENCEPHALOPATHY AFTER TIPS | Stefania Gioia | ![]() |
![]() |
|||
PO-2382 | Role of sex on the development of sarcopenia and ammonia metabolism in bile-duct ligated rats | Mariana M. Oliveira | ![]() |
![]() |
|||
PO-2386 | Dynamic liver function tests and liver elastography in cardiac amyloidosis - preliminary data from AmyKoS | Sandra Ihne | ![]() |
![]() |
|||
PO-2387 | Implementation of a coordinated hepatocellular carcinoma screening program in an outpatient liver center | Joana Vieira Barbosa | ![]() |
![]() |
|||
PO-2388 | FXR Controls Effector Cytokine Production and Phenotype in Biliary Atresia | Annika Yang vom Hofe | ![]() |
![]() |
|||
PO-2389 | Hospitalization Outcomes of Acute Alcoholic Hepatitis with Protein Energy Malnutrition - A nationwide Analysis | Adnan Malik | ![]() |
![]() |
|||
PO-2392 | Liver Involvement is rare during COVID -19 Infection In Children | cigdem Arikan | ![]() |
![]() |
|||
PO-2395 | Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed CHB patients with moderate or severe renal impairment or ESRD on HD: final week 96 efficacy & safety results from a phase 2 study | Harry Janssen | ![]() |
![]() |
|||
PO-2401 | Tailoring the management of HCC during the COVID-19 pandemic: a single center comparative analysis of 4 periods during 2020 versus 2019 | massimo iavarone | ![]() |
![]() |
|||
PO-2403 | A single assessment of acute hemodynamic response to intravenous propranolol predicts hepatic decompensation in cirrhotic patients with portal hypertension | Benedikt S Hofer | ![]() |
![]() |
|||
PO-2408 | The Number of Small Hepatocellular Carcinoma Nodules in Patients within the Alpha-Fetoprotein Score before Liver Transplantation Is a Prognostic Risk Factor | Alina Pascale | ![]() |
![]() |
|||
PO-2411 | Hepatocyte-specific deletion of ERK5 worsens insulin resistance in a murine model of nonalcoholic fatty liver disease | Giulia Lori | ![]() |
![]() |
|||
PO-2412 | Combining non-selective beta blockers with farnesoid X receptor agonists towards ameliorating intestinal barrier dysfunction in non-alcoholic steatohepatitis | Yasmeen Attia | ![]() |
![]() |
|||
PO-2415 | An integrated approach on immune cell subtype characterization reveals common inflammatory pathways in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) | Milessa Afonso | ![]() |
![]() |
|||
PO-2420 | Impact of a loss-of-function variant in HSD17B13 on hepatic decompensation and mortality in cirrhotic patients | Antonio Gil-Gomez | ![]() |
![]() |
|||
PO-2422 | Safety, efficacy, & pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study | Young-Suk Lim | ![]() |
![]() |
|||
PO-2424 | An interactive, country specific, online tool to assess the cost-effectiveness of different hepatitis C testing pathways to inform hepatitis C elimination | Madeline Adee | ![]() |
![]() |
|||
PO-2429 | Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis b | Harry Janssen | ![]() |
![]() |
|||
PO-2456 | Transient Kupffer cell response to microbial components is critically regulated through expression of A20 | Christian Zwicker | ![]() |
![]() |
|||
PO-2474 | Novel HBV cure strategy: Leveraging HBV pol for infected cell-specific killing - In vivo proof-of-concept | Serhat Gumrukcu | ![]() |
![]() |
|||
PO-2476 | Development and multicenter external validation of FIB-6; a novel, machine-learning, simple bedside score to rule out severe liver fibrosis and cirrhosis in patients with chronic hepatitis C | Gamal Shiha | ![]() |
![]() |
|||
PO-2483 | The impact of universal hepatitis B vaccine on the trend of hepatitis B virus attributable liver cancer from Global Burden of Disease Study 2017 | Wen-Qiang He | ![]() |
![]() |
|||
PO-2484 | Nomogram for predicting significant liver injury in chronic hepatitis B patients with immune tolerance | Dong Ji | ![]() |
![]() |
|||
PO-2524 | Quality of life improvement is a top-rated but rarely assessed outcome in European and Australian patients with hepatic encephalopathy: Quality of life targeting and monitoring needs to be prioritised | Juha Halonen | ![]() |
![]() |
|||
PO-2529 | Effects and safety of atrial natriuretic peptide administered to cirrhosis patients with ascites: a systematic review and meta-analysis | Rasmus Hvidbjerg Gantzel | ![]() |
![]() |
|||
PO-2531 | Fluid dynamics analyses of the portal vein flow changes after hepatectomy using 7T 3D PC-MRI | Yu OSHIMA | ![]() |
![]() |
|||
PO-2547 | CLIF-SOFA accurately predicts in-hospital mortality in patients with cirrhosis and bacterial infection | Minjong Lee | ![]() |
![]() |
|||
PO-2572 | Achieving an effective pressure reduction after TIPS for cirrhotic patients with variceal bleeding | Xiaoze Wang | ![]() |
![]() |
|||
PO-2575 | Restoration of HBV-specific immune responses with therapeutic vaccine BRII-179 (VBI-2601) in chronic HBV patients in a phase 1b/2a study | Qing Zhu | ![]() |
![]() |
|||
LBP-2580 | ARO-HSD reduces hepatic HSD17B13 mRNA expression and protein levels in patients with suspected NASH | Edward Gane | ![]() |
![]() |
|||
PO-2583 | Indirect healthcare costs in biopsy-proven NAFLD is higher than in matched controls and independent of comorbidities | Hannes Hagstrm | ![]() |
![]() |
|||
PO-2586 | Uptake of Direct Acting Antivirals for treatment of hepatitis C in human immunodeficiency virus/ hepatits C co-infected children and adolescents in the Russian Federation | Farihah Malik | ![]() |
![]() |
|||
PO-2594 | Free Androgen Index Levels May Influence the Transarterial Chemoembolization with Doxorrubicin-Eluting Beads Response in Hepatocellular Carcinoma Patients: Preliminary Results. | Silvia Acosta-López | ![]() |
![]() |
|||
PO-2596 | Hepatitis C Virus Microelimination is Feasible During COVID-19 Pandemic in Centers for Addiction Treatment Users | Silvia Acosta-Lopez | ![]() |
![]() |
|||
PO-2601 | TIGITTIM-3NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus-related hepatocellular carcinoma | Lihua Yu | ![]() |
![]() |
|||
PO-2609 | Geographic variability in rates of intensive care unit admission in patients with chronic liver disease and critical COVID-19: international registry data | Thomas Marjot | ![]() |
![]() |
|||
PO-2612 | Prior or current hepatocelllular carcinoma does not adversely affect the evolution of LI-RADS 4 lesions. | Louise Hanly | ![]() |
![]() |
|||
PO-2619 | Effects of tenofovir alafenamide fumarate treatment in pregnant women on maternal viral load reduction and preventing mother-to-infant HBV transmission | Huey-Ling Chen | ![]() |
![]() |
|||
PO-2621 | Fixed 8-mm diameter VCX stents do not provide clinical advantages compared to former underdilated VTS stents in cirrhotic patients treated with TIPS for refractory ascites | Sohab Mansour | ![]() |
![]() |
|||
PO-2623 | Myeloid-specific fatty acid transport protein 4 deficiency in mice induces a shift towards M2 macrophages that leads to aggravation of NASH after high-fat/high-cholesterol feeding | Deniz Gcebe | ![]() |
![]() |
|||
PO-2627 | Hepatocytes Caspase6 inhibition exacerbated inflammation and fibrosis in 3D liver spheroids, stellate cells, and the GAN mouse model of NASH | Hani Jouihan | ![]() |
![]() |
|||
PO-2628 | Novel Copper Protein Speciation method for calculating Serum Non Ceruloplasmin Copper: A comparative analysis | Tim Morley | ![]() |
![]() |
|||
PO-2634 | Real-world use of avatrombopag in patients with severe thrombocytopenia associated with chronic liver disease undergoing a procedure | Beverley Wilson | ![]() |
![]() |
|||
PO-2637 | In HBeAg-negative patients within grey zone, serum HBV-RNA levels are higher and more commonly detected, while intrahepatic markers are similar | Adriana Palom | ![]() |
![]() |
|||
PO-2653 | Blocking the CD47-SIRPa axis in nonalcoholic steatohepatitis enhances necroptotic hepatocyte uptake and improves hepatic fibrosis | Hongxue Shi | ![]() |
![]() |
|||
PO-2657 | Patient perspectives on pruritus in intrahepatic cholestasis of pregnancy: a multinational survey | Elaine Chien | ![]() |
![]() |
|||
PO-2667 | Three-fold increased risk for death in Budd-Chiari syndrome compared to matched controls - population-based cohort study | Hannes Hagstrm | ![]() |
![]() |
|||
PO-2673 | Colonic permeability is increased in non-cirrhotic nonalcoholic fatty liver disease | Toon De Munck | ![]() |
![]() |
|||
PO-2681 | Altered DNA methylation characterizes autoimmune hepatitis | Kalliopi Zachou | ![]() |
![]() |
|||
PO-2683 | Validation of a novel point-of-care test for gut leakage in cirrhosis based on dimeric to monomeric IgA ratio: a pilot cohort study | Jessica Howell | ![]() |
![]() |
|||
PO-2684 | MITOCHONDRIAL STRESS IN PATIENTS WITH CHRONIC HEPATITIS B AND ADVANCED FIBROSIS | Dimitri Loureiro | ![]() |
![]() |
|||
PO-2685 | Using dimeric to monomeric IgA ratio to diagnose portal hypertension in liver disease: a pilot cohort study | Jessica Howell | ![]() |
![]() |
|||
PO-2687 | SARS-CoV-2 one year on - the worrying impact on early detection of primary liver cancers | Daniel Geh | ![]() |
![]() |
|||
PO-2688 | Safety and immunogenicity of Coronavirus disease 2019 vaccination in patients with chronic liver disease: a multicenter study | xiaolong qi | ![]() |
![]() |
|||
PO-2689 | Proportion, characteristics, and outcome of chronic hepatitis B who are linked to care in Korea: A nationwide retrospective longitudinal study | Eileen Yoon | ![]() |
![]() |
|||
PO-2695 | FIB-4 based algorithm for screening significant fibrosis in diabetes with or without fatty liver in primary care setting | Eileen Yoon | ![]() |
![]() |
|||
PO-2697 | Defining the range of healthy volunteer non ceruloplasmin copper using a new Copper Protein Speciation assay | Tim Morley | ![]() |
![]() |
|||
PO-2701 | Artificial Intelligence and Digital Single-Operator Cholangioscopy: automatic identification of tumor vessels in patients with indeterminate biliary strictures. | Miguel Mascarenhas | ![]() |
![]() |
|||
PO-2704 | The Alcohol-Associated Liver Disease Paradox in Chile: An Assessment with data from the National Health Survey 2016-2017. | Juan Pablo Roblero | ![]() |
![]() |
|||
PO-2708 | Impact of direct-acting antiviral treatment on mortality related to extrahepatic manifestations: findings from a large population-based cohort in British Columbia, Canada | Dahn Jeong | ![]() |
![]() |
|||
PO-2710 | Gamma-Glutamyl Transpeptidase Dynamics as a Biomarker for Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease | Yeonjung Ha | ![]() |
![]() |
|||
PO-2712 | Real-world experience of atezolizumab/bevacizumab in hepatocellular carcinoma | Yeonjung Ha | ![]() |
![]() |
|||
PO-2719 | Cholangiopathy associated with checkpoint inhibitors: a case series | Philip Berry | ![]() |
![]() |
|||
PO-2724 | Budesonide versus prednisolone in the treatment of autoimmune hepatitis: a cross-sectional patients survey | Ceyhun Aksel Oztumer | ![]() |
![]() |
|||
LBP-2730 | Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study | Maria Gil | ![]() |
![]() |
|||
PO-2732 | Core liver homeostatic networks: implications in therapeutic target discovery, pre-clinical studies, and innovative trial designs | Saeed Esmaili | ![]() |
![]() |
|||
PO-2735 | Durability of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens | Juanjuan Shi | ![]() |
![]() |
|||
PO-2738 | Functional cure based on pegylated interferon a in long-term nucleoside analog suppressed HBeAg negative chronic hepatitis B: A multicenter real-world study(everest project in china), a sequential report the predictors for HBsAg loss | Ze-Qian Wu | ![]() |
![]() |
|||
PO-2739 | In type-2 diabetic patients, the identification of at-risk NASH is impacted by age: a comparison of serum-based NITs including NIS4 | Axelle Louard | ![]() |
![]() |
|||
PO-2742 | Preoperative artemin as predictive biomarker for survival in curatively resected hepatocellular carcinoma | Ulf Zeuge | ![]() |
![]() |
|||
PO-2749 | The combination of ABICELF as a single marker outperforms ABIC alone in predicting 90-day survival in alcoholic hepatitis. | Freya Rhodes | ![]() |
![]() |
|||
PO-2753 | Supplementation of branched-chain amino acids improves event-free survival in cirrhotic patients: systematic review and meta-analysis | Karel J. Van Erpecum | ![]() |
![]() |
|||
PO-2755 | A lesson from COVID19: the persevering benefits of hepatocellular carcinoma surveillance | William Cunliffe | ![]() |
![]() |
|||
PO-2759 | Short-term peginterferon alpha re-treatment induced a high functional cure rate in patients with hepatitis B surface antigen recurrence after cessation of peginterferon alpha-based regimens | Juanjuan Shi | ![]() |
![]() |
|||
PO-2761 | Ischemic cholangiopathy in biliary atresia: immunohistochemical and molecular evidence | Jorge Luiz santos | ![]() |
![]() |
|||
PO-2770 | Optimization of CRISPR/Cas9 technology for a safer treatment of rare metabolic disorders | Laura Torella | ![]() |
![]() |
|||
PO-2786 | Insulin like growth factor-1 as a prognostic tool for overall survival in chronic hepatitis C cirrhotic Egyptian patients with hepatocellular carcinoma | Ahmed Sultan | ![]() |
![]() |
|||
PO-2787 | Identifying effective subtype-specific treatment responses in hepatocellular carcinoma in genetically engineered mouse models | Miryam Mller | ![]() |
![]() |
|||
PO-2788 | Umbilical hernia repair in Cirrhosis: TIPS insertion improves one-year survival but not long-term outcomes | Abdullah Malik | ![]() |
![]() |
|||
PO-2790 | Liver fibrosis accumulation depends on underlying disease aetiology | Adam Watson | ![]() |
![]() |
|||
PO-2791 | Liver test-derived R factor is associated with portal hypertension in patients with non-alcoholic fatty liver disease | Dor Shirin | ![]() |
![]() |
|||
PO-2793 | Disrupted glucose-6-phosphate-ChREBP signalling aggravates hepatomegaly and accelerates liver disease progression in a mouse model for Glycogen Storage Disease type 1a | Martijn Rutten | ![]() |
![]() |
|||
PO-2798 | Phosphoinositide 3-kinase dependent carcinogenesis in the liver | Dayana Tsolova | ![]() |
![]() |
|||
PO-2799 | Early SARS-CoV-2-related mortality of liver cancer patients: Cancer stage matters. | Sergio Muñoz-Martínez | ![]() |
![]() |
|||
PO-2801 | Artificial Intelligence for automatic diagnosis of biliary strictures malignancy status in Single-Operator Cholangioscopy. | Miguel Mascarenhas | ![]() |
![]() |
|||
PO-2812 | Trend and correlates of increased serum alpha-fetoprotein in hepatocellular carcinoma: US National Cancer Database analysis | Aarshi Vipani | ![]() |
![]() |
|||
LBP-2814 | Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress | Sarah Blach | ![]() |
![]() |
|||
PO-2821 | SARS-CoV-2-specific cellular and humoral immunity in COVID-19 convalescence after liver transplantation | Theresa Kirchner | ![]() |
![]() |
|||
PO-2822 | Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA | Emily Thi | ![]() |
![]() |
|||
PO-2823 | Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers | Emily Thi | ![]() |
![]() |
|||
PO-2828 | Characterization of disease progression and pharmacological intervention in the GAN diet-induced obese mouse model of NASH with advanced fibrosis and hepatocellular carcinoma | Michael Feigh | ![]() |
![]() |
|||
PO-2830 | A novel histological scoring system for primary sclerosing cholangitis: Impact on disease outcome | Nelli Sjblom | ![]() |
![]() |
|||
PO-2832 | High prevalence of hormonal changes and hepatic osteodystrophy in Frail patients with cirrhosis An observational study | Surender Singh | ![]() |
![]() |
|||
PO-2833 | Early and late changes in the phenotype of liver sinusoidal endothelial cells (LSECs) along the development of heart failure | Kamila Wojnar-Lason | ![]() |
![]() |
|||
PO-2834 | HBsAg protein composition differs across stages of hepatitia B and hepatitis Delta: a validation cohort study | Luisa Roade | ![]() |
![]() |
|||
PO-2836 | Higher all-cause mortality in individuals living with HIV cured of HCV by direct-acting antivirals compared to HIV mono-infection despite controlled HIV: Results from the ANRS-CO4 FHDH cohort | Maria Requena | ![]() |
![]() |
|||
PO-2839 | A new mouse model of intrahepatic cholangiocarcinoma uncovers a role for TNS4 in tumor progression | Sophie Pirenne | ![]() |
![]() |
|||
PO-2842 | Periods of high or low intensity transplant activity are not associated with changes in liver transplant outcomes | Neil Halliday | ![]() |
![]() |
|||
PO-2844 | A phase 2 study testing FXR agonist Vonafexor in treatment naive patients with chronic hepatitis B (CHB): preliminary week 16 results | Pietro Scalfaro | ![]() |
![]() |
|||
PO-2851 | In vitro skeletal muscle cell atrophy and mitochondrial dysfunction after exposure to human serum from patients with ESLD and NAFLD | Sophie Allen | ![]() |
![]() |
|||
PO-2853 | The incidence of hepatocellular carcinoma in patients with hepatitis B cirrhosis during long-term antiviral therapy: A real world cohort study | Ying Han | ![]() |
![]() |
|||
PO-2858 | Role of the nuclear receptor Farnesoid X Receptor in the immune functions of the intestine in the pathophysiological context of Non Alcoholic SteatoHepatitis | Margaux Nawrot | ![]() |
![]() |
|||
PO-2861 | Projecting the prevalence of obesity- and alcohol- related non-communicable diseases in France, the Netherlands and Romania from 2020 to 2030 using multi-risk microsimulation methods | Lise RETAT | ![]() |
![]() |
|||
PO-2865 | Proteomic profiling of hepatocellular adenomas paves the way to new diagnostic and prognostic approaches | Anne-Aurélie RAYMOND | ![]() |
![]() |
|||
PO-2867 | Hepatogenous diabetes in patients with cirrhosis and ascites: correlation with inflammatory activity, systemic hemodynamics, renal function, and outcome | Ilias Tsiakas | ![]() |
![]() |
|||
PO-2870 | Methylation state of circulating cell-free DNA as a prognostic marker for early to late stage chronic liver disease and acute on chronic liver failure | Aikaterini Tourna | ![]() |
![]() |
|||
PO-2872 | COVID - 19 pandemic and the impact on hospitalization of alcohol related liver disease - A retrospective cohort study in a secondary care setting | Wei Jin Lim | ![]() |
![]() |
|||
PO-2879 | A single dose of the GalNAc-siRNA, AB-729, results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos(t)ide analogue therapy in HBeAg negative subjects with chronic hepatitis B infection | Edward Gane | ![]() |
![]() |
|||
PO-2883 | The intestinal barrier is modified in mice suffering from non-alcoholic steatohepatitis | Simon Peschard | ![]() |
![]() |
|||
LBP-2886 | LPCN 1144 improves body composition in biopsy-confirmed NASH patients | Shadi Mehraban | ![]() |
![]() |
|||
PO-2887 | Artificial intelligence and digital single-operator cholangioscopy: automatic identification of neoplastic biliary nodules in patients with indeterminate biliary stenosis. | Joao Afonso | ![]() |
![]() |
|||
PO-2888 | New insights in CCl4 induced acute liver injury in the presence and absence of Ripk1. | Huma Hameed | ![]() |
![]() |
|||
PO-2890 | A new tool for predicting survival in liver transplantation for hepatocellular carcinoma combining molecular and clinical variables | Joana Cardoso | ![]() |
![]() |
|||
LBP-2891 | Artificial intelligence and digital single-operator cholangioscopy: automatic identification of papillary projections in patients with indeterminate biliary strictures | Tiago Ribeiro | ![]() |
![]() |
|||
PO-2893 | Micro ribonucleic acid- 26a as a diagnostic biomarker for hepatitis C induced hepatocellular carcinoma in Egyptian patients. | Ahmed Sultan | ![]() |
![]() |
|||
PO-2898 | Artificial intelligence and digital single-operator cholangioscopy: automatic identification of neoplastic masses in patients with indeterminate biliary strictures | Tiago RIbeiro | ![]() |
![]() |
|||
PO-2902 | Impact of SarsCov2 pandemic on vascular liver diseases | Anna Baiges | ![]() |
![]() |
|||
PO-2904 | Impact of Universal Automated Hepatitis C Screening with Treatment and Cure in a Primary Care Based Practice | Ruth Brogden | ![]() |
![]() |
|||
LBP-2907 | Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: interim analysis results of the ICONA trial | Stephen Rossi | ![]() |
![]() |
|||
PO-2910 | Liver and/or kidney transplantation after SARS-CoV-2 infection: Prevalence, short-term outcome and kinetics of serum IgG antibodies | Casper Vrij | ![]() |
![]() |
|||
PO-2914 | Fecal microbiota transplantation (FMT) for corticosteroids (CS) non-responders and non-eligible (NoReNE) patients with severe alcoholic hepatitis (SAH). | Natália Bystrianska | ![]() |
![]() |
|||
PO-2919 | Transcriptomic analysis reveals circWHSC1 and circCPSF6 serves as the oncogene to promote hepatocelluar carcinoma progression | Fei Lu | ![]() |
![]() |
|||
PO-2936 | Improving the Accuracy of Non-Invasive Tests for Prediction of Cirrhosis in Chronic Hepatitis Delta: Insights from 230 Patients of the D-LIVR Study | Tarik Asselah | ![]() |
![]() |
|||
PO-2938 | Application of surrogate endpoints in compensated cirrhotic patients with primary biliary cholangitis | Carla Fiorella Murillo Perez | ![]() |
![]() |
|||
PO-2946 | Patients with cirrhosis show an improvement in dynamic liver function following the eradication of hepatitis C virus with direct acting antivirals | Ali Jibran Mecci | ![]() |
![]() |
|||
PO-2951 | An educational intervention that effectively reduces the inappropriate administration of proton pump inhibitors in patients with cirrhosis | Juvelyn Palomique | ![]() |
![]() |
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|